<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11641714</article-id><article-id pub-id-type="pmcid-ver">PMC11641714.1</article-id><article-id pub-id-type="pmcaid">11641714</article-id><article-id pub-id-type="pmcaiid">11641714</article-id><article-id pub-id-type="pmid">39684685</article-id><article-id pub-id-type="doi">10.3390/ijms252312972</article-id><article-id pub-id-type="publisher-id">ijms-25-12972</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bortolot</surname><given-names initials="M">Martina</given-names></name><xref rid="af1-ijms-25-12972" ref-type="aff">1</xref><xref rid="af2-ijms-25-12972" ref-type="aff">2</xref><xref rid="c1-ijms-25-12972" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-2490-0556</contrib-id><name name-style="western"><surname>Torresan</surname><given-names initials="S">Sara</given-names></name><xref rid="af1-ijms-25-12972" ref-type="aff">1</xref><xref rid="af2-ijms-25-12972" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>De Carlo</surname><given-names initials="E">Elisa</given-names></name><xref rid="af1-ijms-25-12972" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8045-6838</contrib-id><name name-style="western"><surname>Bertoli</surname><given-names initials="E">Elisa</given-names></name><xref rid="af1-ijms-25-12972" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0475-7399</contrib-id><name name-style="western"><surname>Stanzione</surname><given-names initials="B">Brigida</given-names></name><xref rid="af1-ijms-25-12972" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1763-0335</contrib-id><name name-style="western"><surname>Del Conte</surname><given-names initials="A">Alessandro</given-names></name><xref rid="af1-ijms-25-12972" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Spina</surname><given-names initials="M">Michele</given-names></name><xref rid="af1-ijms-25-12972" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1020-2338</contrib-id><name name-style="western"><surname>Bearz</surname><given-names initials="A">Alessandra</given-names></name><xref rid="af1-ijms-25-12972" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Ghavami</surname><given-names initials="S">Saeid</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-25-12972"><label>1</label>Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy</aff><aff id="af2-ijms-25-12972"><label>2</label>Department of Medicine (DME), University of Udine, 33100 Udine, Italy</aff><author-notes><corresp id="c1-ijms-25-12972"><label>*</label>Correspondence: <email>martina.bortolot@cro.it</email></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>25</volume><issue>23</issue><issue-id pub-id-type="pmc-issue-id">476804</issue-id><elocation-id>12972</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>27</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-18 14:25:22.613"><day>18</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-25-12972.pdf"/><abstract><p>Although rare in non-small cell lung cancer (NSCLC), BRAF mutations present considerable therapeutic challenges. While the use of BRAF and MEK inhibitor combinations has significantly improved survival outcomes in patients with BRAF V600E mutations, no targeted therapies are currently available for class II and III mutations, leaving the optimal treatment strategy and prognosis for these patients uncertain. Additionally, despite immunotherapy typically showing limited benefit in patients with other activating genomic alterations, it appears to deliver comparable efficacy in BRAF-mutated NSCLC, emerging as a potentially viable treatment option, particularly in patients with a history of smoking. However, resistance to BRAF pathway inhibitors is inevitable, leading to disease progression, and a well-defined strategy to overcome these resistance mechanisms is lacking. This review aims to explore the critical challenges in the management of BRAF-mutated NSCLC, providing a comprehensive summary of the current evidence and highlighting ongoing clinical trials that aim to address these critical gaps.</p></abstract><kwd-group><kwd>NSCLC</kwd><kwd>BRAF non-v600</kwd><kwd>immunotherapy</kwd><kwd>resistant mechanisms</kwd></kwd-group><funding-group><award-group><funding-source>Italian Ministry of Health</funding-source></award-group><funding-statement>This work supported by Italian Ministry of Health (Ricerca Corrente).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-25-12972"><title>1. Introduction</title><p>In NSCLC, mutations of the V-Raf murine sarcoma viral oncogene homolog B (BRAF) gene are rare and detected in approximately 1.5&#8211;2.5% of patients [<xref rid="B1-ijms-25-12972" ref-type="bibr">1</xref>]. These mutations are more frequently observed in never-smokers, women, and aggressive histological subtypes such as micropapillary adenocarcinoma [<xref rid="B1-ijms-25-12972" ref-type="bibr">1</xref>].</p><p>BRAF gene is located on chromosome 7 (7q34) and encodes a serine/threonine-protein kinase involved in the mitogen-activated protein kinase (MAPK) signaling pathway, which regulates cell growth and division. The pathway includes rat sarcoma (RAS)&#8211;rapidly accelerated fibrosarcoma (RAF)&#8211;mitogen-activated protein (MEK)&#8211;extracellular signal-regulated kinase (ERK) [<xref rid="B2-ijms-25-12972" ref-type="bibr">2</xref>] (<xref rid="ijms-25-12972-f001" ref-type="fig">Figure 1</xref>). The signaling cascade begins when growth factors bind to receptor tyrosine kinases (RTKs), triggering RAS activation through GTP binding. Once activated, RAS activates RAF family kinases (ARAF, BRAF, and CRAF), which form functional homo- or heterodimers. These RAF kinases activate MEK, which subsequently phosphorylates and activates ERK, which influences various downstream targets and drives negative feedback mechanisms. Normally, the BRAF kinase is silenced via this negative feedback once the signal advances in the pathway; with BRAF mutations, the RAS&#8211;RAF&#8211;MEK&#8211;ERK pathway remains persistently active, driving uncontrolled cell growth and proliferation.</p><p>The most common BRAF mutations are reported in <xref rid="ijms-25-12972-t001" ref-type="table">Table 1</xref>. With the increasing knowledge of the pathobiology of BRAF variants [<xref rid="B2-ijms-25-12972" ref-type="bibr">2</xref>], three classes of BRAF mutations have been identified based on mutation site and function [<xref rid="B3-ijms-25-12972" ref-type="bibr">3</xref>]. Class I mutations include nucleotide variants, which occur in the valine residue at amino acid position 600 of exon 15, most frequently p.V600E (point mutation T1799A). These mutations result in strong constitutive activation of the BRAF kinase and, therefore, of the MAPK pathway; the mutated BRAF kinase can signal as a monomer, and therefore, it is RAS-independent (RAS activation is even suppressed due to a negative feedback loop after ERK activation) [<xref rid="B4-ijms-25-12972" ref-type="bibr">4</xref>]. Class II mutations, such as L597, G464, and K601 mutations, occur in the activation segment or P-loop; they constitute dimers characterized by high or intermediate kinase activity in vitro (ERK phosphorylation activity is lower than that seen in V600E mutations [<xref rid="B5-ijms-25-12972" ref-type="bibr">5</xref>]), independently of RAS activation. Finally, class III mutations, including D594 and G466, are located in the P-loop, catalytic loop, or DFG motif; unlike the other two groups, they are associated with a lack of or impaired BRAF kinase activity. Thus, the activity of MAPK pathway signaling is dependent on heterodimerization with wild-type RAF protomers and is often enhanced via Raf-1 proto-oncogene CRAF activation. These variants rather serve as amplifiers of upstream signals depending on alternative RAS activation and occur in tumors with high RTK activity or NF1 loss-of-function mutations [<xref rid="B6-ijms-25-12972" ref-type="bibr">6</xref>].</p><p>Although this classification is preclinically validated, its value for clinical prognostication is not well established. In routine clinical practice, BRAF mutations are usually classified as V600 mutations and non-V600 mutations.</p><p>Given the results obtained in patients with advanced melanoma [<xref rid="B7-ijms-25-12972" ref-type="bibr">7</xref>,<xref rid="B8-ijms-25-12972" ref-type="bibr">8</xref>], BRAF inhibitors, such as dabrafenib and vemurafenib, were also evaluated in patients with advanced NSCLC and BRAF mutations, showing promising outcomes [<xref rid="B9-ijms-25-12972" ref-type="bibr">9</xref>,<xref rid="B10-ijms-25-12972" ref-type="bibr">10</xref>,<xref rid="B11-ijms-25-12972" ref-type="bibr">11</xref>]. However, due to the development of various resistance mechanisms and the associated skin toxicity with an enhanced rate of secondary skin malignancies, combination therapies have been explored, suggesting that dual blockade of the BRAF pathway using both BRAF and MEK inhibitors could result in a significantly greater efficacy. In a phase II trial enrolling patients (N = 57) with metastatic BRAF V600E&#8211;mutant NSCLC previously treated with chemotherapy, combination of dabrafenib 150 mg twice daily plus trametinib 2 mg once daily in continuous 21-day cycles provided an objective response rate (ORR) of 63.2%, including 2 (3.5%) patients with complete response (CR) and 34 (59.6%) with partial response (PR). The median progression-free survival (mPFS) rate was 9.7 months, and the 6-month overall survival (OS) rate was 82% [<xref rid="B12-ijms-25-12972" ref-type="bibr">12</xref>]. Further better results were achieved in the untreated population (N = 36, ORR 64% with 6% CR and 58% PR, mPFS 14.6 months, 2-year OS rate 51%) [<xref rid="B13-ijms-25-12972" ref-type="bibr">13</xref>]. Although no phase III trials comparing BRAF/MEK inhibitors and standard chemotherapy +/&#8722; immunotherapy are available, these data led to the approval of this combination as a first-line-strategy in patients with advanced NSCLC and BRAF mutation [<xref rid="B14-ijms-25-12972" ref-type="bibr">14</xref>,<xref rid="B15-ijms-25-12972" ref-type="bibr">15</xref>]. Recently, a combination of encorafenib (anti-BRAF) 450 mg once daily plus binimetinib (anti-MEK) 45 mg twice daily in 28-day cycles also showed clinically meaningful antitumor activity in two phase II trials, either in untreated (ENCOBRAF trial: ORR 66.7%, mPFS 11.1 months; PHAROS trial: ORR 75%, PFS 30.2 months) or pre-treated (PHAROS trial: ORR 46%, mPFS 9.3 months) patients with advanced BRAF-V600E NSCLC, and was approved in this setting [<xref rid="B16-ijms-25-12972" ref-type="bibr">16</xref>].</p><p>However, both strategies are currently recommended and reimbursed only for patients with class I mutations. For those with non-V600 BRAF mutations, the benefit of targeted therapies remains debated and unclear, with chemotherapy still being the preferred treatment. Thus, the question remains open of whether a more targeted approach could also be identified for this subgroup.</p><p>Furthermore, immune checkpoint inhibitors (ICIs) now represent the standard of care (SoC)&#8212;as monotherapy or combined with chemotherapy&#8212;for patients with advanced NSCLC without activating genomic alterations (AGA). Although it has been generally recognized that ICIs would not provide significant benefits to patients with AGA, such as EGFR mutation [<xref rid="B17-ijms-25-12972" ref-type="bibr">17</xref>], the efficacy in BRAF-mutated NSCLC remains to be evaluated.</p><p>Finally, as resistance to BRAF pathway inhibitors inevitably occurs, leading to disease progression, strategies to overcome resistance mechanisms due to activation of alternative pathways, with new drugs or new treatment combinations, are needed.</p><p>In this review, we discuss all these open issues and challenges that clinicians face daily in the treatment of patients with NSCLC and BRAF mutations, summarizing the current data and the ongoing clinical trials.</p></sec><sec id="sec2-ijms-25-12972"><title>2. BRAF Non-V600E</title><sec id="sec2dot1-ijms-25-12972"><title>2.1. Clinical and Molecular Features</title><p>Class II and III comprise half of BRAF mutations in NSCLC, and the most frequent are the G469 group and K601E [<xref rid="B18-ijms-25-12972" ref-type="bibr">18</xref>]. Compared to V600E mutations, they are most likely observed in non-smokers [<xref rid="B19-ijms-25-12972" ref-type="bibr">19</xref>,<xref rid="B20-ijms-25-12972" ref-type="bibr">20</xref>] and are associated with a higher risk of developing brain metastases (<italic toggle="yes">p</italic> &#8804; 0.01) [<xref rid="B21-ijms-25-12972" ref-type="bibr">21</xref>]. </p><p>Different retrospective analyses reported no difference in OS between BRAF V600 and non-V600 mutations [<xref rid="B20-ijms-25-12972" ref-type="bibr">20</xref>,<xref rid="B22-ijms-25-12972" ref-type="bibr">22</xref>], although shorter OS is sometimes described in patients with class III mutations [<xref rid="B23-ijms-25-12972" ref-type="bibr">23</xref>]. </p><p>As per molecular profile, concurrent mutations are more frequently detected with BRAF class II and III mutations, especially class III. The most frequent co-mutations occur in TP53, EGFR, KRAS, and NF1 [<xref rid="B3-ijms-25-12972" ref-type="bibr">3</xref>,<xref rid="B18-ijms-25-12972" ref-type="bibr">18</xref>,<xref rid="B22-ijms-25-12972" ref-type="bibr">22</xref>]. Tumor molecular burden (TMB) appears to be higher in BRAF non-V600E mutant NSCLC, though programmed death-ligand 1 (PDL-1) expression is more often &lt;50% [<xref rid="B19-ijms-25-12972" ref-type="bibr">19</xref>]. However, this finding is not consistent across different studies [<xref rid="B3-ijms-25-12972" ref-type="bibr">3</xref>]. </p><p>In terms of treatment responses, no significant differences have been observed in the effectiveness of chemotherapy across the various mutation classes [<xref rid="B21-ijms-25-12972" ref-type="bibr">21</xref>,<xref rid="B24-ijms-25-12972" ref-type="bibr">24</xref>]. However, in the prospective lung cancer genomic screening project (LC-SCRUM-Asia) enrolling 380 BRAF-mutated NSCLC (119 class I, 122 class II and 86 class III), PFS in response to platinum-containing chemotherapies (5.3 vs. 11.5 months, <italic toggle="yes">p</italic> &lt; 0.01) and OS (14.5 vs. 34.8 months, <italic toggle="yes">p</italic> &lt; 0.02) was significantly shorter in patients with class III as compared with class I [<xref rid="B25-ijms-25-12972" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot2-ijms-25-12972"><title>2.2. Treatment Strategies</title><p>Registrative trials for dabrafenib plus trametinib and encorafenib plus binimetinib in NSCLC enrolled exclusively patients with BRAF V600E mutations [<xref rid="B12-ijms-25-12972" ref-type="bibr">12</xref>,<xref rid="B26-ijms-25-12972" ref-type="bibr">26</xref>]. Most data about the treatment of patients with BRAF non-V600 mutations derive from clinical case reports, a summary of which is reported in <xref rid="ijms-25-12972-t002" ref-type="table">Table 2</xref>. Clinical trials and meta-analyses are difficult to interpret due to the wide range of mutations, drugs, and patient subgroups considered.</p><p>In the phase II BEAVER trial, 23 patients (2 NSCLC) with advanced solid tumors harboring non-V600E mutations, not previously treated with targeted therapy, received encorafenib and binimetinib. ORR was 13% (3/23), and mPFS was 2.4 months. BRAF mutation class was not associated with differences in PFS or ORR, while co-mutation in TP53 was associated with shorter PFS (1.8 vs. 4.0 months, <italic toggle="yes">p</italic> = 0.008) [<xref rid="B40-ijms-25-12972" ref-type="bibr">40</xref>].</p><p>In another single prospective trial, 118 patients with BRAF-mutated NSCLC, of which 17 BRAF non-V600E (4 G466, 4 G469, 1 G596, 5 K601, and 3 N581), were treated with vemurafenib. Only one patient achieved stable disease, with a global ORR of 5.9% and a mPFS of 1.8 months [<xref rid="B41-ijms-25-12972" ref-type="bibr">41</xref>].</p><p>A large meta-analysis examined 238 (58 NSCLC) patients with class II or class III BRAF mutations who received MAPK-targeted therapy. The ORR differed between BRAF mutation classes (41% vs. 13% in class II and class III, respectively; odds ratio 5.12, <italic toggle="yes">p</italic> = 0.002; in NSCLC patients, <italic toggle="yes">p</italic> = 0.018). In addition, mPFS was longer in class II mutated cases (4.6 vs. 2.1 months, HR 0.537, <italic toggle="yes">p</italic> = 0.001; in NSCLC patients, <italic toggle="yes">p</italic> = 0.028). Class II mutant patients also had a better response both to the combination of BRAF and MEK inhibitors or to MEK inhibitors alone compared to class III mutations (RR 56% vs. 27% and 56% vs. 9%, respectively) [<xref rid="B29-ijms-25-12972" ref-type="bibr">29</xref>]. The combination of BRAF and MEK inhibitors was associated with the longest mPFS (5 months) in the whole study population [<xref rid="B42-ijms-25-12972" ref-type="bibr">42</xref>].</p><p>In a retrospective multicohort study that included 35 patients treated with anti-BRAF monotherapy, 6 had BRAF non-V600E mutations (G466V, G469A, G469L, G596V, V600K, and K601E) [<xref rid="B30-ijms-25-12972" ref-type="bibr">30</xref>]. Except for one patient with G596V who achieved PR with vemurafenib, all patients with non-V600E mutations (all located outside of the BRAF kinase domain&#8217;s activation segment) were resistant to anti-BRAF treatment [<xref rid="B10-ijms-25-12972" ref-type="bibr">10</xref>]. Finally, in a retrospective analysis of 30 patients with BRAF nonV600E mutated NSCLC, G469A and L597R mutations (that are associated with high kinase activity) were associated with response to BRAF + MEK inhibitors. Median PFS for patients who received targeted therapy was 3.6 months (95% CI, 1.5&#8211;6.7), and mOS was 7.1 months (95% CI, 1.8-NR) [<xref rid="B43-ijms-25-12972" ref-type="bibr">43</xref>]. The efficacy of dabrafenib and trametinib in those harboring G469A and G466V mutations was confirmed in NSCLC cellular lines [<xref rid="B44-ijms-25-12972" ref-type="bibr">44</xref>].</p></sec><sec id="sec2dot3-ijms-25-12972"><title>2.3. Future Perspectives/New Strategies</title><p>Dedicated trials and, more importantly, a differentiated approach for the various BRAF mutations&#8212;based on a deeper understanding of how they alter intracellular pathways&#8212;are necessary to ensure truly targeted therapies. Current research is increasingly moving in this direction.</p><p>A phase I/II study of binimetinib and encorafenib in advanced solid tumors with BRAF non-V600E activating mutations has recently completed its accrual, and results are awaited (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03843775">NCT03843775</ext-link>).</p><p>New generations of pan-RAF inhibitors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02974725">NCT02974725</ext-link>) and novel RAF-selective TKIs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02428712">NCT02428712</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05538130">NCT05538130</ext-link>) are currently under-evaluation. Exarafenib, for example, is a highly selective pan-RAF inhibitor that demonstrated an encouraging response rate of 64.7% in a phase I clinical trial that is currently ongoing; the same trial is also evaluating the combination of exarafenib and binimetinib [<xref rid="B45-ijms-25-12972" ref-type="bibr">45</xref>].</p><p>As stated, class II BRAF mutations form constitutively active RAF dimers. Therefore, the inhibition of the dimer rather than the BRAF monomer could be effective. Lifirafenib is a BRAF dimer inhibitor that showed promising results in combination with the novel MEK inhibitor mirdametinib, with a synergistic effect. In a dose-finding cohort comprising three patients with BRAF non-V600E mutations (but none of them with NSCLC), the combination showed an ORR of 27.8% [<xref rid="B46-ijms-25-12972" ref-type="bibr">46</xref>]. BGB-3245 is another dimer inhibitor; in a phase Ia/b study enrolling patients with various solid tumors harboring BRAF class II mutations, it showed a DCR of 79% and an ORR of 18% in the overall population [<xref rid="B47-ijms-25-12972" ref-type="bibr">47</xref>]. Further investigation of this drug is ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05580770">NCT05580770</ext-link>), as well as other selective pan-RAF dimer inhibitors (belvarafenib [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03284502">NCT03284502</ext-link>], naporafenib [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02607813">NCT02607813</ext-link>]). A combination of trametinib with lifirafenib and naporafenib suppressed cell growth in the L597V and G469A cell lines more effectively than combinations of cobimetinib plus vemurafenib and binimetinib plus encorafenib [<xref rid="B18-ijms-25-12972" ref-type="bibr">18</xref>] supporting the emerging role of these molecules. Preliminary results of PF-07799933&#8212;another BRAF dimer inhibitor&#8212;in BRAF non-V600E mutated patients are negative (8 patients, with no response) [<xref rid="B48-ijms-25-12972" ref-type="bibr">48</xref>].</p><p>As class III BRAF mutations rely on RAS activity, which in turn depends on feedback from ERK 1/2, targeting ERK presents another potential therapeutic approach currently under investigation. In patients with BRAF nonV600 mutations, ulixertinib&#8212;a reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity&#8212;demonstrated favorable activity in early studies [<xref rid="B49-ijms-25-12972" ref-type="bibr">49</xref>]. In a phase II study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04488003">NCT04488003</ext-link>), however, mPFS resulted in 1.5 (1.0&#8211;2.5) months and mOS 5.2 (3.8&#8211;7.0), leading to a premature discontinuation of the trial. Nonetheless, an expanded access program (EAP) for patients with solid tumors and a mutation in the MAPK pathway remains available (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04566393">NCT04566393</ext-link>), and other ERK1/2 inhibitors are being evaluated (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02857270">NCT02857270</ext-link>). Unfortunately, a limited antitumor activity, despite the observed on-target pharmacodynamic effect, was recently noted in a phase Ib trial regarding the combination of rineterkib&#8212;another ERK1/2 inhibitor&#8212;and naporafenib (n = 101, 3 PR) [<xref rid="B50-ijms-25-12972" ref-type="bibr">50</xref>].</p><p>Other strategies include targeting ULK 1/2, a kinase involved in the autophagy initiation signaling that is inhibited by the inhibition of the MAPK pathway [<xref rid="B51-ijms-25-12972" ref-type="bibr">51</xref>]. Phase I-II studies are underway to explore this option (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04892017">NCT04892017</ext-link>).</p><p>A specific cohort for BRAF class II or III mutations is included in a phase I study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05538130">NCT05538130</ext-link>) evaluating PF-07799544, a next-generation MEK inhibitor alone or in combination with other agents in patients with solid tumors [<xref rid="B52-ijms-25-12972" ref-type="bibr">52</xref>]. Targeting Shock Heat Protein 2 (SHP2) phosphatase with RMC-4550, a small-molecule allosteric inhibitor, resulted effective in human cancer models with class III BRAF mutations [<xref rid="B53-ijms-25-12972" ref-type="bibr">53</xref>].</p></sec></sec><sec id="sec3-ijms-25-12972"><title>3. Role of ICIs in Treatment of BRAF Mutated NSCLC: Is This an Option?</title><sec id="sec3dot1-ijms-25-12972"><title>3.1. Rationale</title><p>The efficacy of ICIs is well established in BRAF-mutant melanoma, but data regarding NSCLC are uncertain and are mainly derived from retrospective studies and case series.</p><p>In the subgroup of patients with BRAF mutation (n = 43) included in the IMMUNOTARGET registry, ORR was 24% and mPFS 3.1 months, supporting the possible efficacy of ICIs in this subgroup [<xref rid="B54-ijms-25-12972" ref-type="bibr">54</xref>]. No significant difference between BRAF V600E and non-V600E mutations in terms of mPFS was observed, while previous or current smokers had better PFS (4.1 vs. 1.9 months) compared to ones who had never smoked [<xref rid="B54-ijms-25-12972" ref-type="bibr">54</xref>]. Similarly, the retrospective chart review by Dudnik et al. analyzed 39 patients with BRAF-mutant NSCLC (21 with V600E mutation and 18 with non-V600E), reporting an ORR of 25% and 33% and a mPFS of 3.7 months and 4.1 months, respectively, in who received ICIs in the two groups [<xref rid="B55-ijms-25-12972" ref-type="bibr">55</xref>]. BRAF-mutational status was not related to the probability of response to immunotherapy or PFS [<xref rid="B55-ijms-25-12972" ref-type="bibr">55</xref>]. Of note, a positive correlation was observed between ICI exposure and OS: mOS was not reached in those treated with nivolumab, pembrolizumab, or atezolizumab monotherapy, and was 21.1 months in those who did not receive ICIs (<italic toggle="yes">p</italic> = 0.018) [<xref rid="B55-ijms-25-12972" ref-type="bibr">55</xref>]. However, imbalances between the ICIs-treated and ICIs-untreated groups (higher PD-L1 expression and TMB in those treated with ICIs, number of previous therapy, and performance status) limit the value of the observation. A sub-analysis of patients (n = 11) with BRAF-mutant NSCLC enrolled in the Italian EAP of second-line nivolumab supported a comparable OS benefit with ICI treatment, regardless of BRAF mutational status (11.2 months in the BRAF wild-type subgroup and 10.3 months in BRAF mutated) [<xref rid="B56-ijms-25-12972" ref-type="bibr">56</xref>].</p><p>Other studies confirmed the possible efficacy of immunotherapy in patients with NSCLC and BRAF mutations but suggested that it is limited to those with non-V600 mutations. Although a similar OS was noticed for patients treated with ICIs both in the BRAF-mutants and in the BRAF wild-type group (10 vs. 11 months, respectively, <italic toggle="yes">p</italic> = 0.334), subgroup analyses of the study by Zhang et al. revealed that the median survival was 14 months in BRAF non-V600E patients and 5 months in the V600E group (<italic toggle="yes">p</italic> = 0.017) [<xref rid="B57-ijms-25-12972" ref-type="bibr">57</xref>]. Also, another retrospective study highlighted lower ORR and mOS (26% vs. 35% and 12.5 vs. 22 months, respectively) in the V600E cohort (n = 26) compared to the non-V600 one (n = 18) in patients with BRAF-mutated NSCLC receiving anti-PD-1 monotherapy [<xref rid="B58-ijms-25-12972" ref-type="bibr">58</xref>]. More recently, a retrospective analysis of NSCLC patients receiving ICI as first-line showed a mPFS and mOS of 7.7 and 27.3 months, respectively, in those with BRAF non-V600E mutations (n = 10), notably longer than the outcomes achieved in the BRAF V600E population (n = 5, mPFS 3.9 months, ORR 40%) [<xref rid="B59-ijms-25-12972" ref-type="bibr">59</xref>]. A profound and sustained response has been documented in a patient with NSCLC and BRAF G469A mutation receiving second-line nivolumab [<xref rid="B34-ijms-25-12972" ref-type="bibr">34</xref>]. Although several other studies explored the outcomes of different classes of BRAF mutations [<xref rid="B16-ijms-25-12972" ref-type="bibr">16</xref>,<xref rid="B60-ijms-25-12972" ref-type="bibr">60</xref>] treated with ICIs, evidence remains inconsistent, and at present, it is not possible to identify subgroups of patients more likely to benefit from this approach.</p><p>Even though there are no prospective trials to confirm it, all the data reported above suggest that immunotherapy has efficacy in BRAF-mutant NSCLC patients and is not different from that observed in the overall NSCLC population. The possible benefit of ICI-based treatments has recently been evidenced not only in the advanced setting but also in the early stage. In a recent analysis, BRAF mutations (both V600 and non-V600) were identified in 4 (3.45%) plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients included in NADIM and NADIM II clinical trials, all of which were cases treated with neoadjuvant chemoimmunotherapy. Although mPFS and mOS were not reached for either BRAF-wild type or BRAF-mutated NSCLC, PFS and OS probabilities at 36 months were 60.5% and 76.1% for patients with BRAF-wild type tumors, while all those with BRAF mutation had no evidence of disease and were alive at data cut-off [<xref rid="B61-ijms-25-12972" ref-type="bibr">61</xref>]. Likewise, BRAF mutations were significantly associated with a higher rate of pathological CR (pCR) after neoadjuvant treatment with chemo-ICIs (100% vs. 44.3%, RR: 2.26; 95% CI 1.78&#8211;2.85; <italic toggle="yes">p</italic> &lt; 0.001) [<xref rid="B61-ijms-25-12972" ref-type="bibr">61</xref>]. Achieving pCR after neoadjuvant chemo-ICIs is strongly associated with prolonged survival [<xref rid="B62-ijms-25-12972" ref-type="bibr">62</xref>]. However, the small sample size does not allow for the establishment of definitive conclusions.</p><p>The better outcomes with ICIs in BRAF-mutated NSCLCs compared to other NSCLCs with AGA are probably due to a higher proportion of current or former smokers [<xref rid="B63-ijms-25-12972" ref-type="bibr">63</xref>]. Smoking status should be considered in the evaluation of an ICI-based treatment as an increased efficacy of immunotherapy was evidenced in smokers, even in patients with oncogenic driver mutations [<xref rid="B64-ijms-25-12972" ref-type="bibr">64</xref>]. Smoking-related cancers often harbor a &#8216;hot&#8217; immune microenvironment, with higher PD-L1 expression and TMB. PD-L1 expression has a recognized predictive value for response to ICIs in NSCLC [<xref rid="B65-ijms-25-12972" ref-type="bibr">65</xref>], and high TMB has emerged as a predictive biomarker for immunotherapy in multiple solid tumors [<xref rid="B66-ijms-25-12972" ref-type="bibr">66</xref>]. High PD-L1 expression (&gt;50%) was observed in up to 50% of patients analyzed (n = 29) in the Dudnik et al. trial (42% in the V600E cohort and 50% in the non-V600E); 2/11 patients showed high TMB [<xref rid="B55-ijms-25-12972" ref-type="bibr">55</xref>]. Zhang et al. reported higher levels of TMB in BRAF-mutated NSCLC compared to the wild-type population (<italic toggle="yes">p</italic> = 0.009) but no significant differences in PD-L1 expression (<italic toggle="yes">p</italic> = 0.198) [<xref rid="B57-ijms-25-12972" ref-type="bibr">57</xref>]. Although a significant association between PD-L1 expression and BRAF mutational status was not demonstrated by Provencio et al., a trend was observed; 2 of 3 BRAF-positive tumors also showed a TMB &#8805; 20 [<xref rid="B62-ijms-25-12972" ref-type="bibr">62</xref>]. More recently, 33.3% of the BRAF-mutated patients (n = 29) analyzed in the Italian ATLAS audit presented a PD-L1 expression rate &gt; 50% [<xref rid="B67-ijms-25-12972" ref-type="bibr">67</xref>].</p><p>In conclusion, based on the current evidence, immunotherapy should be considered for patients with NSCLC and BRAF mutations.</p></sec><sec id="sec3dot2-ijms-25-12972"><title>3.2. When to Consider ICIs</title><p>An increasingly important question is how to integrate ICIs and targeted agents into a potential therapeutic algorithm, particularly given early data suggesting that the combination of immunotherapy and TKIs in NSCLC may raise significant safety concerns [<xref rid="B68-ijms-25-12972" ref-type="bibr">68</xref>].</p><p>While current guidelines recommend the combination of anti-BRAF and anti-MEK therapy as first-line treatment for patients with V600 mutations, single-agent ICIs or combined with chemotherapy (depending on PD-L1 status) should be used as first-line treatment for non-V600 patients. In patients with advanced BRAF V600E NSCLC, combinations of dabrafenib&#8211;trametinib or encorafenib&#8211;binimetinib should be offered upfront, as they are the only regimens with satisfying prospective data in this molecular subset of patients; immunotherapy should be a reasonable option after failure of target therapy. Single-agent ICIs with optional chemotherapy could be considered in patients with a smoking history, while chemotherapy with optional immunotherapy might be suggested for those without a smoking history. As for metastatic NSCLC without AGA, PD-L1 expression can also guide the decision. Moreover, immunotherapy may be proposed as first-line treatment in those countries where targeted therapies are not reimbursed in this setting or in specific cases unfit for TKIs and with features suggesting good outcomes achievable with ICIs (i.e., high PD-L1 or TMB, smoking history).</p><p>Starting with BRAF + MEK inhibition may reduce tumor burden and induce a tumor &#8220;priming&#8221; with the host, paving the way for a subsequent immunotherapeutic approach. Indeed, preclinical data have demonstrated that therapy targeting the MAPK pathway may alter and induce a more favorable tumor microenvironment. MEK inhibitors can upregulate major histocompatibility complex (MHC) I expression and enhance CD8+ T-cell infiltration into tumors (capable of recognizing and destroying tumor cells) [<xref rid="B69-ijms-25-12972" ref-type="bibr">69</xref>]. Additionally, BRAF inhibition is associated with an increased CD4+ and CD8+ lymphocyte infiltrate, higher levels of granzyme B and perforin (which augment cytotoxicity), reduced release of immunosuppressive cytokines such as interleukin-6 and interleukin-8, and decreased levels of myeloid-derived suppressor cells [<xref rid="B70-ijms-25-12972" ref-type="bibr">70</xref>]. All these immunological changes may boost the tumor responses driven by checkpoint blockade, supporting a synergistic activity of BRAF/MEK inhibitors and anti-PD(L)-1 agents. The combination of avutometinib&#8212;a unique RAF/MEK inhibitor that strongly inhibits MEK kinase activity and forms a dominant-negative RAF/MEK complex, preventing MEK phosphorylation by ARAF, BRAF, and CRAF&#8212;and an anti-PD-1 antibody demonstrated enhanced antitumor efficacy and prolonged survival in mouse models compared to the two strategies administered separately [<xref rid="B71-ijms-25-12972" ref-type="bibr">71</xref>].</p><p>Given the promising results achieved in melanoma [<xref rid="B72-ijms-25-12972" ref-type="bibr">72</xref>], ongoing trials are evaluating the combination of immunotherapy and TKIs in patients with NSCLC and BRAF V600 mutation.</p><p>In the subgroup with NSCLC (n = 28) of a phase Ib study investigating the combination of atezolizumab plus cobimetinib, a mOS of 13.2 months and an ORR of 18% were noted, irrespective of BRAF mutational status (only five patients had BRAF mutated NSCLC) [<xref rid="B73-ijms-25-12972" ref-type="bibr">73</xref>]. After these results, cohort E of the phase II/III B-FAST trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03178552">NCT03178552</ext-link>) aims to assess the efficacy (primarily in terms of time to response) and safety of the combination of atezolizumab, vemurafenib, and cobimetinib in patients with advanced NSCLC and BRAF V600 mutations. In the same subgroup, the phase Ib/II umbrella study Landscape 1011 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04585815">NCT04585815</ext-link>) will evaluate the safety and the antitumor activity of subcutaneous sasanlimab (a PD-1 antagonist monoclonal antibody) combined with encorafenib and binimetinib. Phase I is still ongoing, and phase II will focus only on previously untreated patients.</p></sec></sec><sec id="sec4-ijms-25-12972"><title>4. Overcoming BRAF Resistance in NSCLC</title><sec id="sec4dot1-ijms-25-12972"><title>4.1. Resistance Mechanism</title><p>Despite the clinical success of BRAF and MEK inhibitors, clinical trials and real-world data demonstrate that their efficacy is limited by the development of adaptive and acquired resistance within one year. Data on mechanisms of resistance to BRAF/MEK inhibition are scarce in NSCLC and primarily derived from previous studies conducted in BRAF-mutated melanoma.</p><p>The major cause of adaptive drug resistance is the restoration of the MAPK pathway and, therefore, continuous reactivation of ERK signaling. Receptor tyrosine kinases (RTKs) upregulation, secondary mutations of NRAS and KRAS, BRAF amplifications (through either extrachromosomal DNA or intra-chromosomal homogeneously staining regions), or mutations with splice variants, C-RAF or A-RAF overexpression and MEK1/2 mutations have been previously described in melanoma as possible alterations responsible for this MAPK signaling restoration [<xref rid="B74-ijms-25-12972" ref-type="bibr">74</xref>,<xref rid="B75-ijms-25-12972" ref-type="bibr">75</xref>].</p><p>Acquired mutations in KRAS represent the most common off-target resistance mechanism. A case report of a patient with BRAF V600E-mutated advanced NSCLC treated with dabrafenib monotherapy who progressed after an initial response to BRAF inhibition reported a newly acquired KRAS G12D mutation [<xref rid="B76-ijms-25-12972" ref-type="bibr">76</xref>]. In another case report, a KRAS c.35G&gt;T p.(G12V) mutation was detected in a rebiopsy specimen of a patient after progression to dabrafenib plus trametinib treatment; of note, a retrospective analysis of KRAS status in the original biopsy specimen demonstrated that a KRAS mutation was already present in a minute subclone (0.26% fractional abundance) at time of diagnosis [<xref rid="B77-ijms-25-12972" ref-type="bibr">77</xref>]. An NRAS Q61K mutation was identified in both tissue and plasma of another patient with NSCLC who progressed on dual BRAF/MEK inhibition [<xref rid="B78-ijms-25-12972" ref-type="bibr">78</xref>]. More recently, complete molecular profiling conducted at resistance to BRAF/MEK inhibitors in 7 patients from the MATCH-R study identified MEK K57N, KRAS Q61R, and NRAS Q61K mutations [<xref rid="B79-ijms-25-12972" ref-type="bibr">79</xref>].</p><p>The bypass activation of other associated signaling pathways is considered another mechanism of adaptive resistance. A partial crosstalk exists between the MAPK pathway and the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway; RTKs overexpression, phosphatase and tensin homolog (PTEN) loss of function, or activating mutations in phosphatidylinositol 3-kinase catalytic subunit (PI3KC) and AKT have been found to be responsible for resistance to BRAF inhibition [<xref rid="B80-ijms-25-12972" ref-type="bibr">80</xref>,<xref rid="B81-ijms-25-12972" ref-type="bibr">81</xref>].</p><p>Additionally, in a preclinical study of BRAF-mutant cell lines resistant to dual BRAF/MEK inhibition, an adaptive resistance mechanism mediated through the fibroblast growth factor receptor (FGFR) was noted. Two of the four patients analyzed demonstrated an increase in FGF1 expression at progression, resulting in autocrine activation of FGFR, which potentiates ERK activation [<xref rid="B82-ijms-25-12972" ref-type="bibr">82</xref>]. FGFR overexpression has also been reported as a resistant mechanism to MEK inhibition in KRAS-mutated NSCLC models [<xref rid="B83-ijms-25-12972" ref-type="bibr">83</xref>]. The Hippo pathway effector YAP (encoded by YAP1) was identified through a genetic screen in BRAF-mutant tumor cells as an alternative survival mechanism contributing to resistance to anti-RAF and anti-MEK therapy [<xref rid="B84-ijms-25-12972" ref-type="bibr">84</xref>]; increased expression of YAP was a biomarker of worse initial response to RAF and MEK inhibition in patients in tumors harboring BRAF V600E mutations [<xref rid="B84-ijms-25-12972" ref-type="bibr">84</xref>].</p><p>More recently, elevated expression of cyclin-dependent kinase 4 (CDK4) has been reported in patients with NSCLC progressed after dabrafenib-trametinib therapy [<xref rid="B85-ijms-25-12972" ref-type="bibr">85</xref>]; however, the precise mechanisms underlying resistance acquisition have yet to be clarified. Another case report revealed the appearance of MET exon 14 skipping mutation and MET amplification in a patient with oligoprogression during BRAF and MEK inhibition [<xref rid="B86-ijms-25-12972" ref-type="bibr">86</xref>], suggesting the possible role of MET alterations in the acquired resistance to these drugs.</p><p>Other mutations in mixed lineage kinase 1 (MLK1), Ras-related C3 botulinum toxin substrate 1 (RAC1), mitogen-activated protein kinase kinases 1 and 2 (MAP2K1 and MAP2K2, genes that encode for MEK1 and MEK2), amplification of CCND1 and loss of function of CDKN2A also contribute to resistance to RAF and MEK inhibitors [<xref rid="B87-ijms-25-12972" ref-type="bibr">87</xref>,<xref rid="B88-ijms-25-12972" ref-type="bibr">88</xref>].</p><p>The tumor microenvironment could also play a role in the development of resistance. Stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the MAPK and PI(3)K&#8211;AKT signaling pathways, and immediate resistance to RAF inhibition [<xref rid="B89-ijms-25-12972" ref-type="bibr">89</xref>]. Similarly, macrophage-derived TNF&#945; provides resistance to MAPK pathway inhibitors through overexpression of the microphthalmia transcription factor (MITF) [<xref rid="B90-ijms-25-12972" ref-type="bibr">90</xref>]. The production of vascular endothelial growth factor (VEGF) may also lead to ERK pathway reactivation, bypassing BRAF inhibition [<xref rid="B91-ijms-25-12972" ref-type="bibr">91</xref>].</p><p>Finally, other potential targets emerging on BRAF/MEK-resistance were reported in melanoma patients, which may open further treatment options. Three patients initially progressed on immunotherapy as well as BRAF/MEK inhibitors exhibited partial to near-complete responses to poly (ADP-Ribose) polymerase inhibitor (PARPi) therapy combined with BRAF/MEK inhibitors, highlighting the potential synergistic efficacy of this approach [<xref rid="B92-ijms-25-12972" ref-type="bibr">92</xref>].</p></sec><sec id="sec4dot2-ijms-25-12972"><title>4.2. New Strategies</title><p>Several approaches to prevent the development of resistance and/or provide therapeutic alternatives to patients progressed after BRAF and MEK inhibitors are under evaluation (<xref rid="ijms-25-12972-t003" ref-type="table">Table 3</xref>).</p><p>As previously mentioned, ~70% of mechanisms of resistance involve reactivation of the MAPK pathway, resulting in activation of the final kinase, ERK. Downstream inhibition of ERK represents a promising approach to suppress any upstream pathway activation or reactivation. A combination of RAF, MEK, and ERK inhibitors effectively suppressed tumor growth in xenograft models derived from samples of both targeted therapy-naive and pre-treated patients with melanoma or lung cancer and BRAF V600E mutations [<xref rid="B93-ijms-25-12972" ref-type="bibr">93</xref>]. LY3214996, a potent, selective, ATP-competitive ERK1/2 inhibitor, demonstrated antitumor activity in BRAF-mutant models with acquired resistance in vitro and in vivo [<xref rid="B94-ijms-25-12972" ref-type="bibr">94</xref>]. More recently, in a phase II basket trial combining LY3214996 and the CDK 4/6 inhibitor abemaciclib, stable disease was achieved in 33% of patients, with a median disease control rate of 6.5 months. Six of the 12 patients enrolled harbored pathogenic alterations in BRAF, but only 1 had NSCLC [<xref rid="B95-ijms-25-12972" ref-type="bibr">95</xref>]. Although some other studies on the combination of BRAF or MEK inhibitors and CDK 4/6 inhibitors demonstrated promising antitumor activity in melanoma, this was accompanied by significant toxicity, limiting the applicability of this strategy [<xref rid="B96-ijms-25-12972" ref-type="bibr">96</xref>].</p><p>Multi-inhibition of the other different intercommunicating pathways was also investigated in order to delay the acquisition of resistance. Given the crosstalk between their intracellular routes, therapeutic blockade of the PI3K/AKT/mTOR pathway along with the MAPK pathway is a promising treatment approach. The combination of vemurafenib and everolimus (anti-mTOR) demonstrated promising activity in 20 patients with BRAF-mutant advanced cancers (1 NSCLC), including those previously treated with a BRAF inhibitor [<xref rid="B97-ijms-25-12972" ref-type="bibr">97</xref>]. Avutometinib is under evaluation combined with everolimus in RAS-RAF-MEK pathway mutant solid tumors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02407509">NCT02407509</ext-link>). The combination of RAF or MEK inhibition with FGFR inhibitors [<xref rid="B82-ijms-25-12972" ref-type="bibr">82</xref>] or YAP inhibition [<xref rid="B84-ijms-25-12972" ref-type="bibr">84</xref>] appears promising in preclinical investigations, too.</p><p>SHP2 phosphatase is a signal transduction node downstream of multiple RTKs and regulates RAS and MAPK signaling. PF-07284892, an allosteric SHP2 inhibitor, combined with encorafenib and binimetinib, overcame bypass-signaling-mediated resistance in various tumor models, including BRAF V600E-mutant colorectal cancer, presenting a valuable model for testing novel drug combinations [<xref rid="B98-ijms-25-12972" ref-type="bibr">98</xref>].</p><p>Next to new combinatorial strategies, new small molecule inhibitors and targeting agents may help prevent or delay the development of therapeutic resistance. Paradox breakers are novel BRAF V600E inhibitors designed to inhibit BRAF mutant cells impairing BRAF homo/hetero-dimerization but to evade the paradoxical MAPK activation [<xref rid="B99-ijms-25-12972" ref-type="bibr">99</xref>]. The next-generation type 1.5 (&#945;C-helix OUT) RAF inhibitor PLX8394 showed efficacy in treatment-naive BRAF-mutated NSCLC and in cases with acquired vemurafenib resistance, in both V600E and certain non-V600 models [<xref rid="B100-ijms-25-12972" ref-type="bibr">100</xref>]. Currently, HLX208, a novel RAF monomer-selective inhibitor, is being evaluated in combination with trametinib in solid tumors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04965220">NCT04965220</ext-link>). A combination of RAF dimer inhibitor lifirafenib with MEK inhibitor mirdametinib showed antitumor activity in pre-treated several solid tumor types harboring BRAF mutations, including one patient with BRAF V600E NSCLC [<xref rid="B46-ijms-25-12972" ref-type="bibr">46</xref>]. Pan-RAF inhibitors can inhibit both active dimers and active monomers with similar potency, along with other RAF family molecules, avoiding paradoxical activation of the MAPK pathway as well. Belvarafenib&#8212;an oral type II pan-RAF kinase inhibitor&#8212;exhibited promising antitumor activity in a phase I trial enrolling patients with advanced solid tumors with RAS or RAF mutations [<xref rid="B101-ijms-25-12972" ref-type="bibr">101</xref>]. Efficacy and safety of the RAF dimer selective inhibitor naporafenib, in combination with trametinib or with the ERK inhibitor LTT462, is being explored in another phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02974725">NCT02974725</ext-link>) in advanced or metastatic KRAS- or BRAF-mutant NSCLC progressed following standard therapy. Plixorafenib (FORE8394), another selective dimer inhibitor of BRAF, combined with binimetinib, showed robust anticancer activity in cells harboring BRAF V600 or non-V600 mutations or BRAF fusions, higher than the other combinations tested (binimetinib plus vemurafenib or tovorafenib or lifirafenib), representing a promising new strategy in patients with acquired resistance [<xref rid="B102-ijms-25-12972" ref-type="bibr">102</xref>]. PF-07799933 is another new BRAF dimers inhibitor that showed in vitro efficacy in BRAF V600E mutated cells (with even a greater in vitro potency than plixorafenib) and is currently being evaluated in a phase I study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05355701">NCT05355701</ext-link>).</p><p>Finally, the preliminary efficacy of ABM-1310&#8212;another selective BRAF inhibitor&#8212;either alone or in combination with cobimetinib, was seen in 51 patients with advanced BRAF V600-mutated solid tumors, including those who failed previous BRAF &#177; MEK inhibitor treatment (n = 38) [<xref rid="B103-ijms-25-12972" ref-type="bibr">103</xref>]. Specific data regarding NSCLC are missing.</p><p>As regards the co-targeting of MEK, a new generation of selective inhibitors is under evaluation. For example, IMM-6-415, a third-generation dual MEK inhibitor, is being evaluated in a phase I study involving RAS and RAF mutated solid tumors. ABM-168 is another MEK inhibitor that showed in vitro high activity in multiple cancer cell lines with BRAF, RAS, or NF1 mutations and is currently under evaluation in a phase I first-in-human clinical trial [<xref rid="B104-ijms-25-12972" ref-type="bibr">104</xref>].</p><p>All these results support the potential role of next-generation RAF inhibitors beyond BRAF-mutant NSCLC, but further exploration is urgently needed. Moreover, due to the evolving landscape of precision medicine and targeted therapies, they highlight the central role of a comprehensive molecular characterization, both at diagnosis and the time of progression, to detect co-occurring mutations and possible acquired resistance mechanisms, guiding the selection of the optimal treatment strategy.</p><p>Of note, the implementation of a prolonged on-off treatment schedule or the introduction of &#8220;drug holidays&#8221; has been suggested as an alternative strategy in melanoma to promote the expansion of sensitive clones to targeted therapy while allowing for the reduction of resistant clones, thereby preserving tumor responsiveness. However, the real benefit of this approach is uncertain [<xref rid="B105-ijms-25-12972" ref-type="bibr">105</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-25-12972"><title>5. Conclusions</title><p>Despite the rarity of BRAF mutations in NSCLC, research in this area must continue, as many unresolved questions remain. A better understanding of the molecular mechanisms underlying the BRAF pathway and the tumor microenvironment associated with these mutations is essential for accurately characterizing and targeting non-V600 mutations. This knowledge will also aid in integrating targeted therapies with immunotherapy as it appears to be effective in these patients; in particular, ICIs could also be considered as monotherapy in those with BRAF non-V600 mutations, high expression of PD-L1 or TMB and a history of smoking. In addition, exploring new combinations strategies or new molecules (ERK1/2 inhibitors, next-generation RAF inhibitors) to overcome resistance mechanisms is crucial to providing personalized treatment and an effective therapeutic sequence for our patients. This further highlights the relevance of performing tumor tissue rebiopsy at the time of progression and the importance of early access to clinical trials.</p></sec></body><back><ack><title>Acknowledgments</title><p>The image was created on biorender.com.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.B., S.T., E.D.C., E.B., A.B.; writing&#8212;original draft preparation, M.B. and S.T.; writing&#8212;review and editing, M.B., S.T., E.D.C., E.B., B.S., A.D.C., M.S., A.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data sharing is not applicable to this article as no new data were created or analyzed in this study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-25-12972"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen-Ngoc</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bouchaab</surname><given-names>H.</given-names></name><name name-style="western"><surname>Adjei</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name></person-group><article-title>BRAF Alterations as Therapeutic Targets in Non&#8211;Small-Cell Lung Cancer</article-title><source>J. Thorac. Oncol.</source><year>2015</year><volume>10</volume><fpage>1396</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000644</pub-id><pub-id pub-id-type="pmid">26301799</pub-id></element-citation></ref><ref id="B2-ijms-25-12972"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Facchinetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Minari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Friboulet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tiseo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Planchard</surname><given-names>D.</given-names></name></person-group><article-title>BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall</article-title><source>Cancer Treat. Rev.</source><year>2018</year><volume>66</volume><fpage>82</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2018.04.006</pub-id><pub-id pub-id-type="pmid">29729495</pub-id></element-citation></ref><ref id="B3-ijms-25-12972"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yaeger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rodrik-Outmezguine</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cecchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hembrough</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS</article-title><source>Nature</source><year>2017</year><volume>548</volume><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/nature23291</pub-id><pub-id pub-id-type="pmid">28783719</pub-id><pub-id pub-id-type="pmcid">PMC5648058</pub-id></element-citation></ref><ref id="B4-ijms-25-12972"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaeger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>R.B.</given-names></name></person-group><article-title>Targeting alterations in the RAF-MEK pathway</article-title><source>Cancer Discov.</source><year>2019</year><volume>9</volume><fpage>329</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1321</pub-id><pub-id pub-id-type="pmid">30770389</pub-id><pub-id pub-id-type="pmcid">PMC6397699</pub-id></element-citation></ref><ref id="B5-ijms-25-12972"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Garnett</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Niculescu-Duvaz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Good</surname><given-names>V.M.</given-names></name><collab>Cancer Genome Project</collab><name name-style="western"><surname>Jones</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Springer</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</article-title><source>Cell</source><year>2004</year><volume>116</volume><fpage>855</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(04)00215-6</pub-id><pub-id pub-id-type="pmid">15035987</pub-id></element-citation></ref><ref id="B6-ijms-25-12972"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#346;miech</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leszczy&#324;ski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kono</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wardell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>H.</given-names></name></person-group><article-title>Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks</article-title><source>Genes</source><year>2020</year><volume>11</volume><elocation-id>1342</elocation-id><pub-id pub-id-type="doi">10.3390/genes11111342</pub-id><pub-id pub-id-type="pmid">33198372</pub-id><pub-id pub-id-type="pmcid">PMC7697059</pub-id></element-citation></ref><ref id="B7-ijms-25-12972"><label>7.</label><element-citation publication-type="webpage"><article-title>Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma</article-title><source>N. Engl. J. Med.</source><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nejm.org/doi/full/10.1056/NEJMoa1904059" ext-link-type="uri">https://www.nejm.org/doi/full/10.1056/NEJMoa1904059</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-11">(accessed on 11 September 2024)</date-in-citation><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1904059</pub-id><pub-id pub-id-type="pmid">31166680</pub-id></element-citation></ref><ref id="B8-ijms-25-12972"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Dr&#233;no</surname><given-names>B.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>V.</given-names></name><name name-style="western"><surname>Liszkay</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mandal&#224;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Demidov</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stroyakovskiy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>1867</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1408868</pub-id><pub-id pub-id-type="pmid">25265494</pub-id></element-citation></ref><ref id="B9-ijms-25-12972"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Puzanov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Faris</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>I.</given-names></name><name name-style="western"><surname>Blay</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raje</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Hollebecque</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>726</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1502309</pub-id><pub-id pub-id-type="pmid">26287849</pub-id><pub-id pub-id-type="pmcid">PMC4971773</pub-id></element-citation></ref><ref id="B10-ijms-25-12972"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautschi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Milia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cabarrou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bluthgen</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fr&#252;h</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koeberle</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort</article-title><source>J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer</source><year>2015</year><volume>10</volume><fpage>1451</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000625</pub-id><pub-id pub-id-type="pmid">26200454</pub-id></element-citation></ref><ref id="B11-ijms-25-12972"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planchard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Mazieres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quoix</surname><given-names>E.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barlesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Souquet</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial</article-title><source>Lancet Oncol.</source><year>2016</year><volume>17</volume><fpage>642</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)00077-2</pub-id><pub-id pub-id-type="pmid">27080216</pub-id><pub-id pub-id-type="pmcid">PMC5006181</pub-id></element-citation></ref><ref id="B12-ijms-25-12972"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planchard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Souquet</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Quoix</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baik</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Barlesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Mazieres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Novello</surname><given-names>S.</given-names></name><etal/></person-group><article-title>An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E&#8211;mutant metastatic non-small cell lung cancer</article-title><source>Lancet Oncol.</source><year>2016</year><volume>17</volume><fpage>984</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30146-2</pub-id><pub-id pub-id-type="pmid">27283860</pub-id><pub-id pub-id-type="pmcid">PMC4993103</pub-id></element-citation></ref><ref id="B13-ijms-25-12972"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planchard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>H.J.M.</given-names></name><name name-style="western"><surname>Mazieres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Helland</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Giannone</surname><given-names>V.</given-names></name><name name-style="western"><surname>D&#8217;Amelio</surname><given-names>A.M.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mookerjee</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial</article-title><source>Lancet Oncol.</source><year>2017</year><volume>18</volume><fpage>1307</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30679-4</pub-id><pub-id pub-id-type="pmid">28919011</pub-id></element-citation></ref><ref id="B14-ijms-25-12972"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendriks</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>K.</given-names></name><name name-style="western"><surname>Menis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nestle</surname><given-names>U.</given-names></name><name name-style="western"><surname>Passaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Planchard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up&#9734;</article-title><source>Ann. Oncol.</source><year>2023</year><volume>34</volume><fpage>339</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.12.009</pub-id><pub-id pub-id-type="pmid">36872130</pub-id></element-citation></ref><ref id="B15-ijms-25-12972"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network (NCCN)</collab></person-group><article-title>NCCN clinical practice guidelines in oncology</article-title><source>Thorac. Surg. Clin.</source><year>2015</year><volume>25</volume><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">25901562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.thorsurg.2014.12.003</pub-id></element-citation></ref><ref id="B16-ijms-25-12972"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name></person-group><article-title>LBA56&#8212;Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)</article-title><source>Ann. Oncol.</source><year>2024</year><volume>35</volume><fpage>S1246</fpage><lpage>S1247</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2024.08.2298</pub-id></element-citation></ref><ref id="B17-ijms-25-12972"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hastings</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sanchez-Vega</surname><given-names>F.</given-names></name><name name-style="western"><surname>DeVeaux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rizvi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lisberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Truini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>C.</given-names></name><etal/></person-group><article-title>EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>1311</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz141</pub-id><pub-id pub-id-type="pmid">31086949</pub-id><pub-id pub-id-type="pmcid">PMC6683857</pub-id></element-citation></ref><ref id="B18-ijms-25-12972"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negrao</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Lanman</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Robichaux</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Amador</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Roarty</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations</article-title><source>J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer</source><year>2020</year><volume>15</volume><fpage>1611</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.05.021</pub-id><pub-id pub-id-type="pmcid">PMC7529990</pub-id><pub-id pub-id-type="pmid">32540409</pub-id></element-citation></ref><ref id="B19-ijms-25-12972"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Offin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pak</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mondaca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montecalvo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rekhtman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Halpenny</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.</given-names></name><etal/></person-group><article-title>P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers</article-title><source>J. Thorac. Oncol.</source><year>2019</year><volume>14</volume><fpage>S455</fpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.08.942</pub-id></element-citation></ref><ref id="B20-ijms-25-12972"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tissot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanguy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bringuier</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Girard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Souquet</surname><given-names>P.J.</given-names></name></person-group><article-title>Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations</article-title><source>Lung Cancer Amst. Neth.</source><year>2016</year><volume>91</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2015.11.006</pub-id><pub-id pub-id-type="pmid">26711930</pub-id></element-citation></ref><ref id="B21-ijms-25-12972"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagogo-Jack</surname><given-names>I.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yeap</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Ambrogio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jessop</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Iafrate</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.E.</given-names></name><etal/></person-group><article-title>Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2062</pub-id><pub-id pub-id-type="pmid">30224342</pub-id></element-citation></ref><ref id="B22-ijms-25-12972"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiesweg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Preu&#223;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roeper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Metzenmacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eberhardt</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stropiep</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wedeken</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Herold</surname><given-names>T.</given-names></name><name name-style="western"><surname>Darwiche</surname><given-names>K.</given-names></name><etal/></person-group><article-title>BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy</article-title><source>Eur. J. Cancer Oxf. Engl. 1990</source><year>2021</year><volume>149</volume><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.02.036</pub-id><pub-id pub-id-type="pmid">33872981</pub-id></element-citation></ref><ref id="B23-ijms-25-12972"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perrone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mazzaschi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Minari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Verz&#232;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azzoni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bottarelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nizzoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pluchino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Altimari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gruppioni</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring <italic toggle="yes">BRAF</italic> Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>2019</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14082019</pub-id><pub-id pub-id-type="pmid">35454926</pub-id><pub-id pub-id-type="pmcid">PMC9031288</pub-id></element-citation></ref><ref id="B24-ijms-25-12972"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardarella</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ogino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nishino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Butaney</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yeap</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Sholl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>J&#228;nne</surname><given-names>P.A.</given-names></name></person-group><article-title>Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non&#8211;Small Cell Lung Cancer</article-title><source>Clin Cancer Res.</source><year>2013</year><volume>19</volume><fpage>4532</fpage><lpage>4540</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0657</pub-id><pub-id pub-id-type="pmid">23833300</pub-id><pub-id pub-id-type="pmcid">PMC3762878</pub-id></element-citation></ref><ref id="B25-ijms-25-12972"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kodani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Furuya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia)</article-title><source>J. Thorac. Oncol.</source><year>2023</year><volume>18</volume><fpage>1538</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2023.07.024</pub-id><pub-id pub-id-type="pmid">37543207</pub-id></element-citation></ref><ref id="B26-ijms-25-12972"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gelsomino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Esper</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nadal</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients with BRAFV600-Mutant Metastatic Non&#8211;Small-Cell Lung Cancer</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>3700</fpage><lpage>3711</lpage><pub-id pub-id-type="doi">10.1200/JCO.23.00774</pub-id><pub-id pub-id-type="pmid">37270692</pub-id></element-citation></ref><ref id="B27-ijms-25-12972"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautschi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name><name name-style="western"><surname>Aebersold-Keller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Strobel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schwizer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hirschmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Diebold</surname><given-names>J.</given-names></name></person-group><article-title>Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib</article-title><source>Lung Cancer</source><year>2013</year><volume>82</volume><fpage>365</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2013.08.012</pub-id><pub-id pub-id-type="pmid">24035431</pub-id></element-citation></ref><ref id="B28-ijms-25-12972"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagogo-Jack</surname><given-names>I.</given-names></name></person-group><article-title>Durable Response to Dabrafenib Combined with Trametinib in a Patient with NSCLC Harboring a BRAF G469A Mutation</article-title><source>J. Thorac. Oncol.</source><year>2020</year><volume>15</volume><fpage>e174</fpage><lpage>e176</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.07.007</pub-id><pub-id pub-id-type="pmid">32981611</pub-id></element-citation></ref><ref id="B29-ijms-25-12972"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mayo-De-Las-Casas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teixid&#243;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mar&#237;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vollmer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jares</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garz&#243;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molina-Vila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reguart</surname><given-names>N.</given-names></name></person-group><article-title>Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report</article-title><source>Clin. Lung Cancer</source><year>2019</year><volume>20</volume><fpage>e219</fpage><lpage>e223</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2019.02.022</pub-id><pub-id pub-id-type="pmid">30926357</pub-id></element-citation></ref><ref id="B30-ijms-25-12972"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sereno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>G&#243;mez-Raposo</surname><given-names>C.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Jusdado</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Falagan</surname><given-names>S.</given-names></name><name name-style="western"><surname>T&#233;bar</surname><given-names>F.Z.</given-names></name><name name-style="western"><surname>S&#225;enz</surname><given-names>E.C.</given-names></name></person-group><article-title>A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation</article-title><source>Anti-Cancer Drugs</source><year>2015</year><volume>26</volume><fpage>1004</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1097/CAD.0000000000000277</pub-id><pub-id pub-id-type="pmid">26237499</pub-id></element-citation></ref><ref id="B31-ijms-25-12972"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turshudzhyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vredenburgh</surname><given-names>J.</given-names></name></person-group><article-title>A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker</article-title><source>Curr. Oncol.</source><year>2020</year><volume>28</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.3390/curroncol28010021</pub-id><pub-id pub-id-type="pmid">33704186</pub-id><pub-id pub-id-type="pmcid">PMC7816189</pub-id></element-citation></ref><ref id="B32-ijms-25-12972"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: A case report</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2024</year><volume>150</volume><fpage>162</fpage><pub-id pub-id-type="doi">10.1007/s00432-024-05675-9</pub-id><pub-id pub-id-type="pmid">38538919</pub-id><pub-id pub-id-type="pmcid">PMC10972996</pub-id></element-citation></ref><ref id="B33-ijms-25-12972"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fischbach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schott</surname><given-names>R.</given-names></name><name name-style="western"><surname>Somme</surname><given-names>L.</given-names></name></person-group><article-title>Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: A series of case reports and literature review</article-title><source>Front. Oncol.</source><year>2024</year><volume>14</volume><elocation-id>1307882</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2024.1307882</pub-id><pub-id pub-id-type="pmid">38601760</pub-id><pub-id pub-id-type="pmcid">PMC11004365</pub-id></element-citation></ref><ref id="B34-ijms-25-12972"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rittberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Banerji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Green</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qing</surname><given-names>G.</given-names></name><name name-style="western"><surname>E Dawe</surname><given-names>D.</given-names></name></person-group><article-title>Immunotherapy Benefit in a Patient with Non-Small Cell Lung Cancer and a Rare BRAF Mutation</article-title><source>Cureus</source><year>2020</year><volume>12</volume><fpage>e11224</fpage><pub-id pub-id-type="doi">10.7759/cureus.11224</pub-id><pub-id pub-id-type="pmid">33269152</pub-id><pub-id pub-id-type="pmcid">PMC7704186</pub-id></element-citation></ref><ref id="B35-ijms-25-12972"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Do</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Nguyen Thi Bich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C.V.</given-names></name></person-group><article-title>PD-L1-negative non-small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature</article-title><source>Respirol. Case Rep.</source><year>2023</year><volume>11</volume><fpage>e01155</fpage><pub-id pub-id-type="doi">10.1002/rcr2.1155</pub-id><pub-id pub-id-type="pmid">37151366</pub-id><pub-id pub-id-type="pmcid">PMC10156919</pub-id></element-citation></ref><ref id="B36-ijms-25-12972"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>P.-L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Su</surname><given-names>W.-C.</given-names></name></person-group><article-title>Durable Response to Combined Dabrafenib and Trametinib in a Patient with BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report</article-title><source>JTO Clin. Res. Rep.</source><year>2021</year><volume>2</volume><fpage>100202</fpage><pub-id pub-id-type="doi">10.1016/j.jtocrr.2021.100202</pub-id><pub-id pub-id-type="pmid">34590045</pub-id><pub-id pub-id-type="pmcid">PMC8474392</pub-id></element-citation></ref><ref id="B37-ijms-25-12972"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardini</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Chiadini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Faloppi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marisi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Delmonte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scartozzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loretelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lucchesi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oboldi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dubini</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: A case report</article-title><source>BMC Cancer</source><year>2016</year><volume>16</volume><elocation-id>429</elocation-id><pub-id pub-id-type="pmid">27388325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-016-2463-2</pub-id><pub-id pub-id-type="pmcid">PMC4937544</pub-id></element-citation></ref><ref id="B38-ijms-25-12972"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saalfeld</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aust</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Wermke</surname><given-names>M.</given-names></name></person-group><article-title>Targeted Therapy in BRAF p.K601E-Driven NSCLC: Case Report and Literature Review</article-title><source>JCO Precis Oncol.</source><year>2020</year><volume>4</volume><fpage>1163</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1200/PO.20.00187</pub-id><pub-id pub-id-type="pmid">35050775</pub-id></element-citation></ref><ref id="B39-ijms-25-12972"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citarella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Russano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Fazio</surname><given-names>G.-R.</given-names></name><name name-style="western"><surname>Giusti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vincenzi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tonini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>D.</given-names></name></person-group><article-title>Ineffective target therapy in non-small cell lung cancer harboring BRAF G466R mutation: A case report and biological rationale</article-title><source>Precis. Cancer Med.</source><year>2022</year><volume>5</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.21037/pcm-21-24</pub-id></element-citation></ref><ref id="B40-ijms-25-12972"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>A.A.N.</given-names></name><name name-style="western"><surname>Maxwell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rousselle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Riaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tobin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mcguire</surname><given-names>M.</given-names></name><name name-style="western"><surname>King</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kamil</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><fpage>3104</fpage><pub-id pub-id-type="doi">10.1200/JCO.2024.42.16_suppl.3104</pub-id></element-citation></ref><ref id="B41-ijms-25-12972"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazieres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cropet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Montan&#233;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Barlesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Souquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Quantin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dubos-Arvis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Favier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Avrillon</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2019.10.022</pub-id><pub-id pub-id-type="pmid">31959346</pub-id></element-citation></ref><ref id="B42-ijms-25-12972"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dankner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fazelzad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nebhan</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Dagogo-Jack</surname><given-names>I.</given-names></name><name name-style="western"><surname>Myall</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Richtig</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bracht</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Gerlinger</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Clinical Activity of Mitogen-Activated Protein Kinase&#8211;Targeted Therapies in Patients with Non&#8211;V600 BRAF-Mutant Tumors</article-title><source>JCO Precis. Oncol.</source><year>2022</year><volume>6</volume><fpage>e2200107</fpage><pub-id pub-id-type="doi">10.1200/PO.22.00107</pub-id><pub-id pub-id-type="pmid">35977349</pub-id><pub-id pub-id-type="pmcid">PMC10530862</pub-id></element-citation></ref><ref id="B43-ijms-25-12972"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudnik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bshara</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kuznetsov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Shochat</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nechushtan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Onn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agbarya</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non&#8211;Small-Cell Lung Cancer: Findings From a Real-Life Cohort</article-title><source>Clin. Lung Cancer</source><year>2019</year><volume>20</volume><fpage>278</fpage><lpage>286.e1</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2019.03.007</pub-id><pub-id pub-id-type="pmid">31060855</pub-id></element-citation></ref><ref id="B44-ijms-25-12972"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noeparast</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teugels</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giron</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verschelden</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Brakeleer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Decoster</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Gr&#232;ve</surname><given-names>J.</given-names></name></person-group><article-title>Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib</article-title><source>Oncotarget</source><year>2016</year><volume>8</volume><fpage>60094</fpage><lpage>60108</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11635</pub-id><pub-id pub-id-type="pmid">28947956</pub-id><pub-id pub-id-type="pmcid">PMC5601124</pub-id></element-citation></ref><ref id="B45-ijms-25-12972"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mehnert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chmielowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Millward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Gambardella</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mckean</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brose</surname><given-names>M.</given-names></name><etal/></person-group><article-title>613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) &amp; BRAF-altered solid tumors</article-title><source>Ann. Oncol.</source><year>2024</year><volume>35</volume><fpage>S491</fpage><lpage>S492</lpage></element-citation></ref><ref id="B46-ijms-25-12972"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Millward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sbar</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Abstract CT033: Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><fpage>CT033</fpage></element-citation></ref><ref id="B47-ijms-25-12972"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schram</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cosman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sbar</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amoruccio</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer in-hibitor BGB-3245 in patients with advanced or refractory tumors</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><issue>(Suppl. S8)</issue><fpage>CT031</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2023-CT031</pub-id></element-citation></ref><ref id="B48-ijms-25-12972"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaeger</surname><given-names>R.</given-names></name><name name-style="western"><surname>McKean</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Haq</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bowles</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mihalcioiu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>K.P.</given-names></name><etal/></person-group><article-title>A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation</article-title><source>Cancer Discov.</source><year>2024</year><volume>14</volume><fpage>1599</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-24-0024</pub-id><pub-id pub-id-type="pmid">38691346</pub-id><pub-id pub-id-type="pmcid">PMC11372368</pub-id></element-citation></ref><ref id="B49-ijms-25-12972"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Janku</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D.J.L.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Keedy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Mier</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Tolcher</surname><given-names>A.W.</given-names></name><etal/></person-group><article-title>First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study</article-title><source>Cancer Discov.</source><year>2018</year><volume>8</volume><fpage>184</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1119</pub-id><pub-id pub-id-type="pmid">29247021</pub-id></element-citation></ref><ref id="B50-ijms-25-12972"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planchard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>M.</given-names></name></person-group><article-title>A phase Ib study of the combination of naporafenib with rineterkib or tra-metinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer</article-title><source>Lung Cancer</source><year>2024</year><volume>197</volume><fpage>107964</fpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2024.107964</pub-id><pub-id pub-id-type="pmid">39383771</pub-id></element-citation></ref><ref id="B51-ijms-25-12972"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamopoulos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Papavassiliou</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Poulikakos</surname><given-names>P.I.</given-names></name><name name-style="western"><surname>Papavassiliou</surname><given-names>A.G.</given-names></name></person-group><article-title>RAF and MEK Inhibitors in Non-Small Cell Lung Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>4633</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25094633</pub-id><pub-id pub-id-type="pmid">38731852</pub-id><pub-id pub-id-type="pmcid">PMC11083651</pub-id></element-citation></ref><ref id="B52-ijms-25-12972"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Shepard</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Dumas</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pezo</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>A.A.N.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wollenberg</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><fpage>TPS3180</fpage></element-citation></ref><ref id="B53-ijms-25-12972"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Haderk</surname><given-names>F.</given-names></name><name name-style="western"><surname>Stahlhut</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hemmati</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wildes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tzitzilonis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mordec</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marquez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>J.</given-names></name><etal/></person-group><article-title>RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers</article-title><source>Nat. Cell Biol.</source><year>2018</year><volume>20</volume><fpage>1064</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0169-1</pub-id><pub-id pub-id-type="pmid">30104724</pub-id><pub-id pub-id-type="pmcid">PMC6115280</pub-id></element-citation></ref><ref id="B54-ijms-25-12972"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazieres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Drilon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lusque</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Mhanna</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cortot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mezquita</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thai</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Mascaux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Veillon</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>1321</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz167</pub-id><pub-id pub-id-type="pmid">31125062</pub-id><pub-id pub-id-type="pmcid">PMC7389252</pub-id></element-citation></ref><ref id="B55-ijms-25-12972"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudnik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nechushtan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wollner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Onn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agbarya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moskovitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Popovits-Hadari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>D.</given-names></name><etal/></person-group><article-title>BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors</article-title><source>J. Thorac. Oncol.</source><year>2018</year><volume>13</volume><fpage>1128</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.04.024</pub-id><pub-id pub-id-type="pmid">29723688</pub-id></element-citation></ref><ref id="B56-ijms-25-12972"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rihawi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Giannarelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Galetta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Delmonte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giavarra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Turci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garassino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tiseo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barbieri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Panni</surname><given-names>S.</given-names></name><etal/></person-group><article-title>BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience</article-title><source>J. Thorac. Oncol.</source><year>2019</year><volume>14</volume><fpage>e57</fpage><lpage>e59</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.11.036</pub-id><pub-id pub-id-type="pmid">30782386</pub-id></element-citation></ref><ref id="B57-ijms-25-12972"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Patients with BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint In-hibitors: A Population-Based Study</article-title><source>JTO Clin. Res. Rep.</source><year>2020</year><volume>1</volume><fpage>100006</fpage><pub-id pub-id-type="pmid">34589911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtocrr.2020.100006</pub-id><pub-id pub-id-type="pmcid">PMC8474360</pub-id></element-citation></ref><ref id="B58-ijms-25-12972"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guisier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dubos-Arvis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vi&#241;as</surname><given-names>F.</given-names></name><name name-style="western"><surname>Doubre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ricordel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ropert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Janicot</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fournel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lamy</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients with Advanced NSCLC with BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018</article-title><source>J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer</source><year>2020</year><volume>15</volume><fpage>628</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.12.129</pub-id><pub-id pub-id-type="pmid">31945494</pub-id></element-citation></ref><ref id="B59-ijms-25-12972"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: A multicenter real-world analysis</article-title><source>Transl. Lung Cancer Res.</source><year>2024</year><volume>13</volume><fpage>861</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.21037/tlcr-24-116</pub-id><pub-id pub-id-type="pmid">38736501</pub-id><pub-id pub-id-type="pmcid">PMC11082706</pub-id></element-citation></ref><ref id="B60-ijms-25-12972"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negrao</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Skoulidis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Montesion</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bara</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>D.</given-names></name><name name-style="western"><surname>Elamin</surname><given-names>Y.Y.</given-names></name><etal/></person-group><article-title>Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>e002891</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-002891</pub-id><pub-id pub-id-type="pmid">34376553</pub-id><pub-id pub-id-type="pmcid">PMC8356172</pub-id></element-citation></ref><ref id="B61-ijms-25-12972"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Provencio</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Lope</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Serna-Blasco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nadal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tain</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Massuti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Larriba</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Insa</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#225;nchez-Hern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casal-Rubio</surname><given-names>J.</given-names></name><etal/></person-group><article-title>BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC</article-title><source>Lung Cancer</source><year>2024</year><volume>194</volume><fpage>107865</fpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2024.107865</pub-id><pub-id pub-id-type="pmid">38945004</pub-id></element-citation></ref><ref id="B62-ijms-25-12972"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Provencio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nadal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Larriba</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Mart&#237;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bernab&#233;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bosch-Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casal-Rubio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Insa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ponce</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Perioperative Nivolumab and Chemotherapy in Stage III Non&#8211;Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>504</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2215530</pub-id><pub-id pub-id-type="pmid">37379158</pub-id></element-citation></ref><ref id="B63-ijms-25-12972"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paik</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Arcila</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Fara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sima</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Kris</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Ladanyi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name></person-group><article-title>Clinical characteristics of patients with lung adenocarcinomas harboring <italic toggle="yes">BRAF</italic> mutations</article-title><source>J. Clin. Oncol.</source><year>2011</year><volume>29</volume><fpage>2046</fpage><lpage>2051</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.33.1280</pub-id><pub-id pub-id-type="pmid">21483012</pub-id><pub-id pub-id-type="pmcid">PMC3107760</pub-id></element-citation></ref><ref id="B64-ijms-25-12972"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riudavets</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auclin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mosteiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dempsey</surname><given-names>N.</given-names></name><name name-style="western"><surname>Majem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lobefaro</surname><given-names>R.</given-names></name><name name-style="western"><surname>L&#243;pez-Castro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bosch-Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pilotto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Escalera</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Durvalumab consolidation in patients with un-resectable stage III non-small cell lung cancer with driver genomic alterations</article-title><source>Eur. J. Cancer</source><year>2022</year><volume>167</volume><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.02.014</pub-id><pub-id pub-id-type="pmid">35307254</pub-id></element-citation></ref><ref id="B65-ijms-25-12972"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy</article-title><source>Mol. Cancer</source><year>2020</year><volume>19</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s12943-020-1144-6</pub-id><pub-id pub-id-type="pmid">32000802</pub-id><pub-id pub-id-type="pmcid">PMC6993488</pub-id></element-citation></ref><ref id="B66-ijms-25-12972"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Budzcies</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kluck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stenzinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sinicrope</surname><given-names>F.A.</given-names></name></person-group><article-title>Tumor Mutational Burden (TMB) as a Predictive Biomarker in Solid Tumors</article-title><source>Cancer Discov.</source><year>2020</year><volume>10</volume><fpage>1808</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0522</pub-id><pub-id pub-id-type="pmid">33139244</pub-id><pub-id pub-id-type="pmcid">PMC7710563</pub-id></element-citation></ref><ref id="B67-ijms-25-12972"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malapelle</surname><given-names>U.</given-names></name><name name-style="western"><surname>Passiglia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pepe</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pisapia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reale</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Cortinovis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fraggetta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Galetta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garbo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Graziano</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database</article-title><source>Lung Cancer</source><year>2024</year><volume>191</volume><fpage>107787</fpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2024.107787</pub-id><pub-id pub-id-type="pmid">38593479</pub-id></element-citation></ref><ref id="B68-ijms-25-12972"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adderley</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blackhall</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>C.R.</given-names></name></person-group><article-title>Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer</article-title><source>Cancer Immunol. Immunother.</source><year>2020</year><volume>70</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02714-5</pub-id><pub-id pub-id-type="pmid">32915318</pub-id><pub-id pub-id-type="pmcid">PMC7907017</pub-id></element-citation></ref><ref id="B69-ijms-25-12972"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebert</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McNamara</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moskalenko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Maecker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Irving</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade</article-title><source>Immunity</source><year>2016</year><volume>44</volume><fpage>609</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.01.024</pub-id><pub-id pub-id-type="pmid">26944201</pub-id></element-citation></ref><ref id="B70-ijms-25-12972"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilmott</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Long</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Howle</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Haydu</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kefford</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Hersey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Scolyer</surname><given-names>R.A.</given-names></name></person-group><article-title>Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma</article-title><source>Clin. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>1386</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2479</pub-id><pub-id pub-id-type="pmid">22156613</pub-id></element-citation></ref><ref id="B71-ijms-25-12972"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arcas</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Downward</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pachter</surname><given-names>J.A.</given-names></name></person-group><article-title>Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immu-nogenic tumor microenvironment and potentiates the efficacy of anti-PD-1</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><issue>(Suppl. S7)</issue><fpage>4155</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2023-4155</pub-id></element-citation></ref><ref id="B72-ijms-25-12972"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dimitriou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gutzmer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name></person-group><article-title>Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in <italic toggle="yes">BRAF</italic>V600 Melanoma: Current Status and Future Perspectives</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>5489</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14225489</pub-id><pub-id pub-id-type="pmid">36428582</pub-id><pub-id pub-id-type="pmcid">PMC9688939</pub-id></element-citation></ref><ref id="B73-ijms-25-12972"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hellmann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.-W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>B.-C.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>W.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>D.-Y.</given-names></name><name name-style="western"><surname>Jamal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chee</surname><given-names>C.-E.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gainor</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>1134</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz113</pub-id><pub-id pub-id-type="pmid">30918950</pub-id><pub-id pub-id-type="pmcid">PMC6931236</pub-id></element-citation></ref><ref id="B74-ijms-25-12972"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Allen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Wagle</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sucker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Treacy</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Johannessen</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Goetz</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Place</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Taylor-Weiner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kryukov</surname><given-names>G.V.</given-names></name><etal/></person-group><article-title>The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma</article-title><source>Cancer Discov.</source><year>2014</year><volume>4</volume><fpage>94</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0617</pub-id><pub-id pub-id-type="pmid">24265153</pub-id><pub-id pub-id-type="pmcid">PMC3947264</pub-id></element-citation></ref><ref id="B75-ijms-25-12972"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazarian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Koya</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.-K.</given-names></name><name name-style="western"><surname>Attar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sazegar</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</article-title><source>Nature</source><year>2010</year><volume>468</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09626</pub-id><pub-id pub-id-type="pmid">21107323</pub-id><pub-id pub-id-type="pmcid">PMC3143360</pub-id></element-citation></ref><ref id="B76-ijms-25-12972"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudin</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Streit</surname><given-names>M.</given-names></name></person-group><article-title>Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non&#8211;Small-Cell Lung Cancer</article-title><source>J. Thorac. Oncol.</source><year>2013</year><volume>8</volume><fpage>e41</fpage><lpage>e42</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e31828bb1b3</pub-id><pub-id pub-id-type="pmid">23524406</pub-id><pub-id pub-id-type="pmcid">PMC3634121</pub-id></element-citation></ref><ref id="B77-ijms-25-12972"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemantsverdriet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schuuring</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ter Elst</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Wekken</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>van Kempen</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>H.J.</given-names></name></person-group><article-title>KRAS mutation as a resistance mechanism to BRAF/MEK inhibition in NSCLC</article-title><source>J. Thorac. Oncol.</source><year>2018</year><volume>13</volume><fpage>e249</fpage><lpage>e251</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.07.103</pub-id><pub-id pub-id-type="pmid">30467046</pub-id></element-citation></ref><ref id="B78-ijms-25-12972"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abravanel</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Nishino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sholl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Ambrogio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Awad</surname><given-names>M.M.</given-names></name></person-group><article-title>An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib</article-title><source>J. Thorac. Oncol.</source><year>2018</year><volume>13</volume><fpage>e131</fpage><lpage>e133</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.03.026</pub-id><pub-id pub-id-type="pmid">29631033</pub-id><pub-id pub-id-type="pmcid">PMC7102421</pub-id></element-citation></ref><ref id="B79-ijms-25-12972"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Facchinetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lacroix</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mezquita</surname><given-names>L.</given-names></name><name name-style="western"><surname>Scoazec</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Loriot</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tselikas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gazzah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rouleau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Michiels</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non&#8211;small cell lung cancer</article-title><source>Eur. J. Cancer</source><year>2020</year><volume>132</volume><fpage>211</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2020.03.025</pub-id><pub-id pub-id-type="pmid">32388065</pub-id></element-citation></ref><ref id="B80-ijms-25-12972"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hugo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koya</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Moriceau</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chodon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Dahlman</surname><given-names>K.B.</given-names></name><etal/></person-group><article-title>Acquired resistance and clonal evolution in Melanoma during BRAF inhibitor therapy</article-title><source>Cancer Discov.</source><year>2014</year><volume>4</volume><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0642</pub-id><pub-id pub-id-type="pmid">24265155</pub-id><pub-id pub-id-type="pmcid">PMC3936420</pub-id></element-citation></ref><ref id="B81-ijms-25-12972"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Koya</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moriceau</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hugo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chodon</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A Novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition</article-title><source>Cancer Discov.</source><year>2014</year><volume>4</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0279</pub-id><pub-id pub-id-type="pmid">24265152</pub-id><pub-id pub-id-type="pmcid">PMC3893054</pub-id></element-citation></ref><ref id="B82-ijms-25-12972"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Frederick</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Urisman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Bernards</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>7202</fpage><lpage>7217</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2779</pub-id><pub-id pub-id-type="pmid">31515463</pub-id><pub-id pub-id-type="pmcid">PMC6891193</pub-id></element-citation></ref><ref id="B83-ijms-25-12972"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manchado</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weissmueller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Wullenkord</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lujambio</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Stanchina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Gainor</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>R.B.</given-names></name><etal/></person-group><article-title>A combinatorial strategy for treating KRAS-mutant lung cancer</article-title><source>Nature</source><year>2016</year><volume>534</volume><fpage>647</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1038/nature18600</pub-id><pub-id pub-id-type="pmid">27338794</pub-id><pub-id pub-id-type="pmcid">PMC4939262</pub-id></element-citation></ref><ref id="B84-ijms-25-12972"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sabnis</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Olivas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cade</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pazarentzos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies</article-title><source>Nat. Genet.</source><year>2015</year><volume>47</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1038/ng.3218</pub-id><pub-id pub-id-type="pmid">25665005</pub-id><pub-id pub-id-type="pmcid">PMC4930244</pub-id></element-citation></ref><ref id="B85-ijms-25-12972"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hatanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hatanaka</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Uno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>S.-I.</given-names></name><name name-style="western"><surname>Umekage</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Minami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ohsaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>T.</given-names></name></person-group><article-title>Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer</article-title><source>Transl. Lung Cancer Res.</source><year>2021</year><volume>10</volume><fpage>3737</fpage><lpage>3744</lpage><pub-id pub-id-type="doi">10.21037/tlcr-21-415</pub-id><pub-id pub-id-type="pmid">34733624</pub-id><pub-id pub-id-type="pmcid">PMC8512466</pub-id></element-citation></ref><ref id="B86-ijms-25-12972"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pluchino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Testi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Minari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dodi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Air&#242;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mazzaschi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Verz&#232;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adorni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gnetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Azzoni</surname><given-names>C.</given-names></name><etal/></person-group><article-title>MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient</article-title><source>Anti-Cancer Drugs</source><year>2024</year><volume>35</volume><fpage>761</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1097/CAD.0000000000001623</pub-id><pub-id pub-id-type="pmid">39115059</pub-id></element-citation></ref><ref id="B87-ijms-25-12972"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marusiak</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>Z.C.</given-names></name><name name-style="western"><surname>Hugo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Trotter</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Girotti</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gartside</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Fawdar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mixed lineage kinases activate MEK inde-pendently of RAF to mediate resistance to RAF inhibitors</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3901</fpage><pub-id pub-id-type="doi">10.1038/ncomms4901</pub-id><pub-id pub-id-type="pmid">24849047</pub-id><pub-id pub-id-type="pmcid">PMC4046110</pub-id></element-citation></ref><ref id="B88-ijms-25-12972"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nathanson</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Wubbenhorst</surname><given-names>B.</given-names></name><name name-style="western"><surname>Greshock</surname><given-names>J.</given-names></name><name name-style="western"><surname>Letrero</surname><given-names>R.</given-names></name><name name-style="western"><surname>D&#8217;Andrea</surname><given-names>K.</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>S.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Falchook</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Arkenau</surname><given-names>H.-T.</given-names></name><etal/></person-group><article-title>Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)</article-title><source>Clin. Cancer Res.</source><year>2013</year><volume>19</volume><fpage>4868</fpage><lpage>4878</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0827</pub-id><pub-id pub-id-type="pmid">23833299</pub-id><pub-id pub-id-type="pmcid">PMC3924894</pub-id></element-citation></ref><ref id="B89-ijms-25-12972"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Straussman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barzily-Rokni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mongare</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frederick</surname><given-names>D.T.</given-names></name><etal/></person-group><article-title>Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</article-title><source>Nature</source><year>2012</year><volume>487</volume><fpage>500</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1038/nature11183</pub-id><pub-id pub-id-type="pmid">22763439</pub-id><pub-id pub-id-type="pmcid">PMC3711467</pub-id></element-citation></ref><ref id="B90-ijms-25-12972"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Sanchez-Laorden</surname><given-names>B.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brunton</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dhomen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Frederick</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>Z.A.</given-names></name><etal/></person-group><article-title>The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF&#945;</article-title><source>Cancer Discov.</source><year>2014</year><volume>4</volume><fpage>1214</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-1007</pub-id><pub-id pub-id-type="pmid">25256614</pub-id><pub-id pub-id-type="pmcid">PMC4184867</pub-id></element-citation></ref><ref id="B91-ijms-25-12972"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Krepler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Belser</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lopez-Coral</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>1652</fpage><lpage>1664</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1554</pub-id><pub-id pub-id-type="pmid">25617424</pub-id><pub-id pub-id-type="pmcid">PMC4383683</pub-id></element-citation></ref><ref id="B92-ijms-25-12972"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillipps</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nassief</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morecroft</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adeyelu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vanderwalde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Butt</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma</article-title><source>npj Precis. Oncol.</source><year>2024</year><volume>8</volume><fpage>187</fpage><pub-id pub-id-type="doi">10.1038/s41698-024-00684-w</pub-id><pub-id pub-id-type="pmid">39232122</pub-id><pub-id pub-id-type="pmcid">PMC11374802</pub-id></element-citation></ref><ref id="B93-ijms-25-12972"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Martelotto</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baslan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vides</surname><given-names>A.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>K.</given-names></name><etal/></person-group><article-title>An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>929</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1038/nm.4369</pub-id><pub-id pub-id-type="pmid">28714990</pub-id><pub-id pub-id-type="pmcid">PMC5696266</pub-id></element-citation></ref><ref id="B94-ijms-25-12972"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhagwat</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>McMillen</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Whitesell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kindler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Flack</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>B.</given-names></name><etal/></person-group><article-title>ERK Inhibitor LY3214996 Targets ERK Pathway&#8211;Driven Cancers: A Therapeutic Approach Toward Precision Medicine</article-title><source>Mol. Cancer Ther.</source><year>2020</year><volume>19</volume><fpage>325</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0183</pub-id><pub-id pub-id-type="pmid">31744895</pub-id></element-citation></ref><ref id="B95-ijms-25-12972"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Durm</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Opyrchal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jalal</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Radovich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Turk</surname><given-names>A.A.</given-names></name></person-group><article-title>A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><issue>(Suppl. S16)</issue><fpage>e15088</fpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.16_suppl.e15088</pub-id></element-citation></ref><ref id="B96-ijms-25-12972"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panagiotou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gomatou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Trontzas</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Syrigos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kotteas</surname><given-names>E.</given-names></name></person-group><article-title>Cyclin-dependent kinase (CDK) inhibitors in solid tumors: A review of clinical trials</article-title><source>Clin. Transl. Oncol.</source><year>2021</year><volume>24</volume><fpage>161</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1007/s12094-021-02688-5</pub-id><pub-id pub-id-type="pmid">34363593</pub-id></element-citation></ref><ref id="B97-ijms-25-12972"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khawaja</surname><given-names>M.R.-U.</given-names></name><name name-style="western"><surname>Khatua</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karp</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Janku</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsimberidou</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Zaky</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Co-targeting BRAF with mTOR inhibition in solid tumors harboring <italic toggle="yes">BRAF</italic> mutations: A phase I study</article-title><source>J. Clin. Oncol.</source><year>2016</year><volume>34</volume><fpage>2517</fpage><pub-id pub-id-type="doi">10.1200/JCO.2016.34.15_suppl.2517</pub-id></element-citation></ref><ref id="B98-ijms-25-12972"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drilon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Yap</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nepert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Harney</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Elsayed</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy</article-title><source>Cancer Discov.</source><year>2023</year><volume>13</volume><fpage>1789</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-23-0361</pub-id><pub-id pub-id-type="pmid">37269335</pub-id><pub-id pub-id-type="pmcid">PMC10401072</pub-id></element-citation></ref><ref id="B99-ijms-25-12972"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koumaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kontogianni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kosmidou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pahitsa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kritsi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zervou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chatziioannou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Souliotis</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Papadodima</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pintzas</surname><given-names>A.</given-names></name></person-group><article-title>BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600&#917; CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2021</year><volume>1867</volume><elocation-id>166061</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.166061</pub-id><pub-id pub-id-type="pmid">33385518</pub-id></element-citation></ref><ref id="B100-ijms-25-12972"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okimoto</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Olivas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Markegard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rymar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hemmati</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bollag</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <italic toggle="yes">BRAF</italic> -mutant lung cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>13456</fpage><lpage>13461</lpage><pub-id pub-id-type="doi">10.1073/pnas.1610456113</pub-id><pub-id pub-id-type="pmid">27834212</pub-id><pub-id pub-id-type="pmcid">PMC5127364</pub-id></element-citation></ref><ref id="B101-ijms-25-12972"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>H.-S.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><fpage>3000</fpage><pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.3000</pub-id></element-citation></ref><ref id="B102-ijms-25-12972"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Filippov-Levy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Billauer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Birnbaum</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gasasa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Abu-Liel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tarcic</surname><given-names>G.</given-names></name></person-group><article-title>The paradox-breaker BRAF inhibitor plixo-rafenib (PLX8394; FORE8394) synergizes with MEK inhibitors (MEKi) in BRAF V600 and non-V600 alterations, with higher potency compared to early generation BRAFi and pan-RAFi</article-title><source>Cancer Res.</source><year>2024</year><volume>84</volume><issue>(Suppl. S6)</issue><fpage>4609</fpage></element-citation></ref><ref id="B103-ijms-25-12972"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piha-Paul</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>De La Fuente</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nagpal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weise</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><issue>(Suppl. S16)</issue><fpage>3107</fpage><pub-id pub-id-type="doi">10.1200/JCO.2024.42.16_suppl.3107</pub-id></element-citation></ref><ref id="B104-ijms-25-12972"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Abstract 475: Preclinical development of ABM-168, a novel MEK Inhibitor to treat cancer with brain tumors</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><fpage>475</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2023-475</pub-id></element-citation></ref><ref id="B105-ijms-25-12972"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Algazi</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Othus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daud</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Mehnert</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Conry</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kendra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Doolittle</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.I.</given-names></name><etal/></person-group><article-title>Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: A randomized phase 2 trial</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1564</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1060-8</pub-id><pub-id pub-id-type="pmid">33020646</pub-id><pub-id pub-id-type="pmcid">PMC8063889</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-25-12972-f001" orientation="portrait"><label>Figure 1</label><caption><p>BRAF pathway with the most recognized resistance mechanism highlighted. Red arrows indicate the main signaling chain. <bold>GOF</bold>&#8212;<italic toggle="yes">gain of function</italic>; <bold>LOF</bold>&#8212;<italic toggle="yes">loss of function</italic>; <bold>EGFR</bold>&#8212;<italic toggle="yes">Epidermal Growth Factor Receptor</italic>; <bold>RTKs</bold>&#8212;<italic toggle="yes">Receptor Tyrosine Kinases</italic>; <bold>GRB2</bold>&#8212;<italic toggle="yes">Growth Factor Receptor-Bound Protein 2</italic>; <bold>SHP</bold>&#8212;<italic toggle="yes">Src Homology Phosphatases</italic>; <bold>GEFs</bold>&#8212;<italic toggle="yes">Guanine nucleotide Exchange Factors</italic>; <bold>RAS</bold>&#8212;<italic toggle="yes">Rat Sarcoma</italic>; <bold>NF1</bold>&#8212;<italic toggle="yes">Neurofibromin 1</italic>; <bold>RAF</bold>&#8212;<italic toggle="yes">Rapidly Accelerated Fibrosarcoma</italic>; <bold>MEK</bold>&#8212;<italic toggle="yes">Mitogen-Activated Protein Kinase</italic>; <bold>ERK</bold>&#8212;<italic toggle="yes">Extracellular Signal-Regulated Kinase</italic>; <bold>PI3K</bold>&#8212;<italic toggle="yes">Phosphoinositide 3-Kinase</italic>; <bold>AKT</bold>&#8212;<italic toggle="yes">Protein Kinase B</italic>; <bold>PTEN</bold>&#8212;<italic toggle="yes">Phosphatase and Tensin Homolog</italic>; <bold>MLK1</bold>&#8212;<italic toggle="yes">Mixed-Lineage Kinase 1</italic>; <bold>FGF1</bold>&#8212;<italic toggle="yes">Fibroblast Growth Factor 1</italic>; <bold>FGFR</bold>&#8212;<italic toggle="yes">Fibroblast Growth Factor Receptor</italic>; <bold>COT</bold>&#8212;<italic toggle="yes">Cot/Tpl2</italic>; <bold>YAP</bold>&#8212;<italic toggle="yes">Yes-Associated Protein</italic>; <bold><italic toggle="yes">STATs</italic></bold>&#8212;<italic toggle="yes">Signal Transducer and Activator of Transcription</italic>; <bold><italic toggle="yes">cMYC</italic></bold>&#8212;<italic toggle="yes">Cellular MYC</italic>; <bold><italic toggle="yes">ELK1</italic></bold>&#8212;<italic toggle="yes">ETS-Like Protein 1</italic>; <bold><italic toggle="yes">NF-kB</italic></bold>&#8212;<italic toggle="yes">Nuclear Factor kappa B</italic>; <bold><italic toggle="yes">RSK</italic></bold>&#8212;<italic toggle="yes">Ribosomal S6 Kinase</italic>; <bold><italic toggle="yes">AP-1</italic></bold>&#8212;<italic toggle="yes">Activator Protein 1</italic>; <bold><italic toggle="yes">CDK2NA</italic></bold>&#8212;<italic toggle="yes">Cyclin-Dependent Kinase Inhibitor 2A</italic>; <bold><italic toggle="yes">MAP2K</italic></bold>&#8212;<italic toggle="yes">Mitogen-Activated Protein Kinase Kinase</italic>; <bold><italic toggle="yes">CCND1</italic></bold>&#8212;<italic toggle="yes">Cyclin D1</italic>; <bold><italic toggle="yes">RAC1</italic></bold>&#8212;<italic toggle="yes">Ras-Related C3 Botulinum Toxin Substrate 1</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-25-12972-g001.jpg"/></fig><table-wrap position="float" id="ijms-25-12972-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-25-12972-t001_Table 1</object-id><label>Table 1</label><caption><p>Most frequent BRAF mutations in NSCLC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mutation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nucleotide Change</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AA Change</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Location in the Protein</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">V600E</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">1799</td><td align="center" valign="middle" rowspan="1" colspan="1">T&gt;A</td><td align="center" valign="middle" rowspan="1" colspan="1">Activation segment</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V600K</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">1798_1799</td><td align="center" valign="middle" rowspan="1" colspan="1">delinsAA</td><td align="center" valign="middle" rowspan="1" colspan="1">Activation segment</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V600R</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">1798_1799</td><td align="center" valign="middle" rowspan="1" colspan="1">GT&gt;AG</td><td align="center" valign="middle" rowspan="1" colspan="1">Activation segment</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L597Q</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">1790</td><td align="center" valign="middle" rowspan="1" colspan="1">T&gt;A</td><td align="center" valign="middle" rowspan="1" colspan="1">Activation segment</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L597R</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">1790</td><td align="center" valign="middle" rowspan="1" colspan="1">T&gt;G</td><td align="center" valign="middle" rowspan="1" colspan="1">Activation segment</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K6001E</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">1801</td><td align="center" valign="middle" rowspan="1" colspan="1">A&gt;G</td><td align="center" valign="middle" rowspan="1" colspan="1">Activation segment</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G464V</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">1391</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;T</td><td align="center" valign="middle" rowspan="1" colspan="1">P-loop</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G469A</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">1406</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;C</td><td align="center" valign="middle" rowspan="1" colspan="1">Glycine-rich region</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G469E</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">1406</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;A</td><td align="center" valign="middle" rowspan="1" colspan="1">Glycine-rich region</td><td align="center" valign="middle" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G469R</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">1405</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;A</td><td align="center" valign="middle" rowspan="1" colspan="1">Glycine-rich region</td><td align="center" valign="middle" rowspan="1" colspan="1">Unknown</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G466R</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1396</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;A</td><td align="center" valign="middle" rowspan="1" colspan="1">P-loop</td><td align="center" valign="middle" rowspan="1" colspan="1">Impaired kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G466A</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1397</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;C</td><td align="center" valign="middle" rowspan="1" colspan="1">P-loop</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G466V</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1397</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;T</td><td align="center" valign="middle" rowspan="1" colspan="1">P-loop</td><td align="center" valign="middle" rowspan="1" colspan="1">Impaired kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">D594E</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1782</td><td align="center" valign="middle" rowspan="1" colspan="1">T&gt;G</td><td align="center" valign="middle" rowspan="1" colspan="1">DFG motif</td><td align="center" valign="middle" rowspan="1" colspan="1">Impaired kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">D594G</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1781</td><td align="center" valign="middle" rowspan="1" colspan="1">A&gt;G</td><td align="center" valign="middle" rowspan="1" colspan="1">DFG motif</td><td align="center" valign="middle" rowspan="1" colspan="1">Impaired kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">D594H</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1780</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;C</td><td align="center" valign="middle" rowspan="1" colspan="1">DFG motif</td><td align="center" valign="middle" rowspan="1" colspan="1">Impaired kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">D594N</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1780</td><td align="center" valign="middle" rowspan="1" colspan="1">G&gt;A</td><td align="center" valign="middle" rowspan="1" colspan="1">DFG motif</td><td align="center" valign="middle" rowspan="1" colspan="1">Impaired kinase activity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">N581Sa</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1742</td><td align="center" valign="middle" rowspan="1" colspan="1">A&gt;G</td><td align="center" valign="middle" rowspan="1" colspan="1">Catalytic loop</td><td align="center" valign="middle" rowspan="1" colspan="1">Activate kinase activity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G596R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1786</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G&gt;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DFG motif</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Impaired kinase activity</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-25-12972-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-25-12972-t002_Table 2</object-id><label>Table 2</label><caption><p>Case reports of BRAF non-V600 NSCLC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BRAF Mutation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Co-Mutations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Detection Technique</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Best Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PFS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Case Report</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G469L</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanger sequencing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vemurafenib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gautschi et al. [<xref rid="B27-ijms-25-12972" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G469A</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib/trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dagogo-Jack et al. [<xref rid="B28-ijms-25-12972" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G469V</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">APC</italic> R1040fs&#8727;16 and CHD2 L1383&#8727; mutations and <italic toggle="yes">NFKBIA</italic> and <italic toggle="yes">NKX2-1</italic> amplifications</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib/trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negrao et al. [<xref rid="B18-ijms-25-12972" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>L597R</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">none</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib/trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR at 12 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negrao et al. [<xref rid="B18-ijms-25-12972" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>D594G</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">TP53</italic> H193L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negrao et al. [<xref rid="B18-ijms-25-12972" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G469A and W604C</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">none</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib/trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR at 15 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reyes et al. [<xref rid="B29-ijms-25-12972" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G469R</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">TP53 E68, ATRE2209, STK11S69, ATK11 F354L mutations; PI3KCA, PDGFRA, Kit, KDR amplifications and CDKN2A loss.</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorafenib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sereno et al. [<xref rid="B30-ijms-25-12972" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>p.T599dup</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">none</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sanger sequencing and NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib/trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR at 4 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Turshudzhyan et al. [<xref rid="B31-ijms-25-12972" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>p.T599dup</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">TP53 exon 8 p.V272M missense mutation, BRCA2 exon 11 missense mutation andCTNNB1 exon 3 missense mutation.</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib/trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jiang et al. [<xref rid="B32-ijms-25-12972" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G596R</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">NR</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT-IO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lazar et al. [<xref rid="B33-ijms-25-12972" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G464V</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">NR</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lazar et al. [<xref rid="B33-ijms-25-12972" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G469V</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">NR</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT-IO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR at 18 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lazar et al. [<xref rid="B33-ijms-25-12972" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G469A</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">NR</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR at 4 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rittberg et al. [<xref rid="B34-ijms-25-12972" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>E501Q</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">none</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT-IO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR at 3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Do et al. [<xref rid="B35-ijms-25-12972" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>K601E</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">EGFR amplification (copy number: 2.36) and RICTOR amplification (copy number: 2.74)</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib/trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Su et al. [<xref rid="B36-ijms-25-12972" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G469V</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">none</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorafenib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Casadei-Gardini et al. [<xref rid="B37-ijms-25-12972" ref-type="bibr">37</xref>] Concomitant HCC</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>K601E</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">FGFR4 and ALK VUS</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saalfeld et al. [<xref rid="B38-ijms-25-12972" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G466R</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">NF1 I70fs*15</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib/trametinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citarella et al. [<xref rid="B39-ijms-25-12972" ref-type="bibr">39</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>PFS = progression-free survival, PD = progression disease, SD = stable disease, PR = partial response, CR = complete response, NGS = next-generation sequencing, NR = not reached.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-25-12972-t003" orientation="portrait"><object-id pub-id-type="pii">ijms-25-12972-t003_Table 3</object-id><label>Table 3</label><caption><p>Ongoing trials in BRAF-mutated NSCLC. BRAFi = BRAF inhibitor, NOS = not otherwise specified, RAFi = RAF inhibitor, MEKi = MEK inhibitor, ICI = immune checkpoint inhibitor, NS = not specified, NSCLC = non-small cell lung cancer, ULK1/2i = ULK1/2 inhibitor.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mutation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Setting</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Experimental Arm</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06054191">NCT06054191</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF V600</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">perioperatory</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib plus trametinib</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05800340">NCT05800340</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF (any confirmed driver)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neoadjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toripalimab plus chemotherapy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06563999">NCT06563999</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF V600E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neoadjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib plus trametinib</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05786924">NCT05786924</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All BRAF and CRAF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2nd line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BDTX-4933 (BRAFi)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05355701">NCT05355701</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All BRAF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PF-07799933 (BRAFi) +/&#8722; binimetinib</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06270082">NCT06270082</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF class II-III and fusions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IK-595 (Dual MEK/RAFi)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04913285">NCT04913285</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All BRAF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No previous BRAFi allowed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIN-2787 (RAFi) +/&#8722; binimetinib</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06326411">NCT06326411</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAPK pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No previous BRAFi allowed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NST-628 (Pan-RAF/MEKi)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05501912">NCT05501912</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF V600</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ABM-1310 (BRAFi)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05538130">NCT05538130</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF class II/III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PF-07799544 (MEKi) +/&#8722; PF-07799933</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03284502">NCT03284502</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All RAF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HM95573 (RAFi) + cobimetinib</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02407509">NCT02407509</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAS-RAF-MEK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VS-6766 (RAF/MEki) +/&#8722; everolimus</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04965220">NCT04965220</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All BRAF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No previous BRAFi allowed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLX208 (BRAF V600E Inhibitor)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05275374">NCT05275374</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-IIa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF V600</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XP-102 (RAFi) plus trametinib</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05641493">NCT05641493</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ib-II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF V600E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No previous BRAFi or ICI allowed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLX208 plus serplulimab (anti-PD-1 monoclonal antibody)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05900219">NCT05900219</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF V600E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-085 (MEKi) plus Vemurafenib</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05580770">NCT05580770</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-IIa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAPK pathway, NSCLC cohort BRAF class II-III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BGB-3245 (RAFi)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06287463">NCT06287463</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAPK pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS (prior treatment with certain BRAF dimer inhibitors not allowed)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCC-3084 (RAFi)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04985604">NCT04985604</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ib-II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAPK pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic NOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tovorafenib (RAFi)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04892017">NCT04892017</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I-II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAS, NF1, or RAF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2nd line and beyond</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCC-3116 (ULK1/2i)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06074588">NCT06074588</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF V600E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3rd line and beyond</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sacituzumab Tirumotecan (MK-2870) vs. docetaxel/pemetrexed</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>